Spaces:

FINAL-Bench
/

open-discovery-challenge

Running

App Files Files Community

open-discovery-challenge / index.html

SeaWolf-AI

submit: 429 재시도 + 접수를 한 커밋으로 + JSON 아닌 오류 본문 처리

490c9ea verified 20 days ago

Raw

History Blame Contribute Delete

133 kB

	<!doctype html>
	<html lang="ko">
	<head>
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width,initial-scale=1">
	<title>Open Discovery Challenge #1 Malaria</title>
	<!-- An explicit <head> is not optional here: the platform injects its own tags into the
	document, and with no head to receive them they land ahead of the doctype, which
	drops the whole page into quirks mode. -->
	<style>
	:root{
	--bg:#f6f8fc; --panel:#ffffff; --line:#e3e9f2; --ink:#131a26; --muted:#65748c;
	--accent:#0f7b6c; --accent-soft:#e6f5f2; --anchor:#b4740a; --anchor-soft:#fdf4e3;
	--bad:#b3261e; --bar:#0f7b6c; --bar-bg:#eef2f8;
	--shadow:0 1px 2px rgba(19,26,38,.05),0 8px 24px rgba(19,26,38,.06);
	}
	*{box-sizing:border-box}
	html,body{margin:0;padding:0}
	body{background:var(--bg);color:var(--ink);
	font:15px/1.6 -apple-system,"Segoe UI",Roboto,"Malgun Gothic","Apple SD Gothic Neo",sans-serif;
	-webkit-font-smoothing:antialiased}
	.wrap{max-width:1180px;margin:0 auto;padding:26px 20px 70px}

	header{position:relative;background:linear-gradient(135deg,#ffffff 0%,#eef6f4 55%,#e7f0fb 100%);
	border:1px solid var(--line);border-radius:16px;padding:26px 28px;box-shadow:var(--shadow)}
	.ms{margin:0 0 14px;padding:11px 15px;border-radius:10px;font-size:13.5px;line-height:1.65;
	background:linear-gradient(120deg,#f4fbf6 0%,#eef7fb 100%);border:1px solid #cfe6d8;color:#1f4a35}
	.ms b{font-weight:800}
	.ms .n{font-family:var(--m,monospace);font-weight:850;letter-spacing:-.03em}

	#cd{margin:0 0 14px}
	#cd .cdlab{display:block;font-size:10.5px;font-weight:700;letter-spacing:2px;
	text-transform:uppercase;color:var(--muted);margin-bottom:2px}
	#cd .cdval{display:block;font-family:ui-monospace,Menlo,Consolas,monospace;
	font-size:38px;font-weight:800;letter-spacing:-1px;color:#0f1b2d;
	line-height:1.05;font-variant-numeric:tabular-nums;
	/* the digits change every second; without a fixed advance the whole line
	jitters as glyph widths swap under it */
	font-feature-settings:"tnum" 1}
	#cd .cdval .d{color:var(--accent)}
	#cd.over .cdval{color:var(--muted)}
	@media(max-width:720px){#cd .cdval{font-size:28px}}
	.eyebrow{color:var(--accent);font-size:11.5px;font-weight:700;letter-spacing:2.4px;
	text-transform:uppercase;margin:0 0 6px}
	h1{margin:0;font-size:30px;letter-spacing:-.5px;font-weight:800}
	h1 em{font-style:normal;color:var(--accent)}
	.concept{margin:12px 0 0;font-size:19px;font-weight:700;letter-spacing:-.2px;
	color:#1c2a3d;line-height:1.4;max-width:34ch}
	.concept b{color:var(--accent)}
	.sub{color:var(--muted);font-size:14px;margin:10px 0 0;max-width:70ch}
	.wts{display:flex;flex-wrap:wrap;gap:7px;margin-top:16px}
	.wts span{font-size:11.5px;font-weight:600;color:#31465e;background:#fff;
	border:1px solid var(--line);border-radius:20px;padding:4px 12px}
	.wts b{color:var(--accent)}

	#intro{margin:0 0 16px;border-radius:14px;overflow:hidden;border:1px solid var(--line);
	background:#0d1420;line-height:0;box-shadow:var(--shadow)}
	#intro:empty{display:none;margin:0;border:0}
	#intro video{width:100%;height:auto;display:block}
	#intro .credit{line-height:1.5;font-size:11px;color:#8ea3c0;background:#0d1420;
	padding:7px 12px;text-align:right}
	#seasonbar{display:flex;gap:6px;margin-bottom:14px}
	.pager{display:flex;align-items:center;justify-content:center;gap:6px;
	flex-wrap:wrap;padding:14px 4px 2px;font-size:13px}
	.pager button{border:1px solid var(--line);background:#fff;color:var(--muted);
	border-radius:8px;padding:5px 11px;cursor:pointer;font:inherit;min-width:36px}
	.pager button:hover:not(:disabled){border-color:var(--accent);color:var(--accent)}
	.pager button.on{background:var(--accent);color:#fff;border-color:var(--accent)}
	.pager button:disabled{opacity:.4;cursor:default}
	.pager .pinfo{color:var(--muted);margin:0 8px}
	.pager .gap{color:var(--muted);padding:0 2px}
	#seasonbar button{border:1px solid var(--line);background:#fff;color:var(--muted);
	font:inherit;font-size:12.5px;font-weight:700;padding:7px 14px;
	border-radius:999px;cursor:pointer;display:flex;align-items:center;
	gap:7px}
	#seasonbar button.on{background:var(--accent);color:#fff;border-color:var(--accent)}
	#seasonbar .st{font-size:10px;font-weight:800;letter-spacing:.04em;padding:1px 6px;
	border-radius:999px;background:#eef3fa;color:var(--muted)}
	#seasonbar button.on .st{background:rgba(255,255,255,.22);color:#fff}
	@media(max-width:720px){#seasonbar{flex-wrap:wrap}}
	#tally{position:absolute;top:62px;right:22px;display:flex;gap:8px;z-index:5}
	#tally .t{background:#fff;border:1px solid var(--line);border-radius:10px;
	padding:6px 11px;box-shadow:var(--shadow);text-align:right;line-height:1.15}
	#tally .t b{display:block;font-size:16px;font-weight:800;color:#16223a;
	font-variant-numeric:tabular-nums}
	#tally .t span{font-size:9.5px;color:var(--muted);letter-spacing:.02em}
	@media(max-width:860px){#tally{position:static;margin:0 0 12px;justify-content:flex-start}}
	#langbar{position:absolute;top:20px;right:22px;display:flex;gap:2px;background:#fff;
	border:1px solid var(--line);border-radius:9px;padding:3px;box-shadow:var(--shadow)}
	#langbar button{border:0;background:transparent;color:var(--muted);font:inherit;
	font-size:12px;font-weight:700;padding:5px 11px;border-radius:6px;cursor:pointer}
	#langbar button.on{background:var(--accent);color:#fff}
	#langnote{position:absolute;top:56px;right:22px;font-size:10.5px;color:var(--muted)}

	.how{margin-top:20px;background:var(--panel);border:1px solid var(--line);
	border-radius:16px;padding:20px 22px;box-shadow:var(--shadow)}
	.how h2{margin:0 0 6px;font-size:13px;letter-spacing:1.4px;text-transform:uppercase;color:var(--muted)}
	.how .why{color:#31465e;font-size:13.5px;margin:0 0 16px;max-width:88ch}
	.steps{display:grid;grid-template-columns:repeat(3,1fr);gap:14px}
	@media(max-width:820px){.steps{grid-template-columns:1fr}}
	.step{position:relative;background:#fbfcfe;border:1px solid var(--line);
	border-radius:12px;padding:14px 16px 15px}
	.step .n{position:absolute;top:-10px;left:14px;width:24px;height:24px;border-radius:50%;
	background:var(--accent);color:#fff;font-size:12px;font-weight:800;
	display:flex;align-items:center;justify-content:center;
	box-shadow:0 2px 6px rgba(15,123,108,.3)}
	.step h3{margin:8px 0 5px;font-size:14px;font-weight:800}
	.step p{margin:0;font-size:12.5px;color:var(--muted);line-height:1.65}
	.models{display:flex;flex-wrap:wrap;gap:5px;margin-top:9px}
	.models span{font-size:10.5px;font-weight:700;color:#31465e;background:#fff;
	border:1px solid var(--line);border-radius:6px;padding:2px 7px}
	#authbar{position:absolute;top:20px;right:150px;display:flex;align-items:center;gap:8px}
	#authbar .u{display:flex;align-items:center;gap:7px;background:#fff;border:1px solid var(--line);
	border-radius:9px;padding:4px 10px 4px 5px;box-shadow:var(--shadow);font-size:12.5px;font-weight:700}
	#authbar .u img{width:22px;height:22px;border-radius:50%;display:block}
	#authbar .u a{color:var(--muted);text-decoration:none;font-weight:600;font-size:11px;margin-left:2px}
	.hfbtn{display:inline-flex;align-items:center;gap:7px;background:#111827;color:#fff;
	border:0;border-radius:9px;padding:8px 13px;font:inherit;font-size:12.5px;
	font-weight:700;cursor:pointer;text-decoration:none;box-shadow:var(--shadow)}
	.hfbtn:hover{background:#000}
	.gate{margin-top:14px;background:#fff8ea;border:1px solid #f0dfba;border-radius:10px;
	padding:12px 13px;font-size:12.5px;color:#7a5a12;line-height:1.6}
	.gate .hfbtn{margin-top:9px;width:100%;justify-content:center}

	#ov{position:fixed;z-index:50;display:none;width:340px;background:#fff;
	border:1px solid var(--line);border-radius:14px;padding:15px 16px;
	box-shadow:0 12px 40px rgba(19,26,38,.18)}
	#ov h4{margin:0 0 2px;font-size:14px;font-weight:800;letter-spacing:-.2px}
	#ov .oid{font-size:11px;color:var(--muted);font-family:ui-monospace,monospace;margin-bottom:10px}
	#ov .orow{display:grid;grid-template-columns:60px 1fr 42px;gap:8px;align-items:center;
	padding:5px 0;border-top:1px solid #f0f3f8;font-size:11.5px}
	#ov .orow:first-of-type{border-top:0}
	#ov .oax{color:var(--muted);font-weight:700}
	#ov .obar{height:5px;border-radius:3px;background:var(--bar-bg);overflow:hidden}
	#ov .obar i{display:block;height:100%;background:var(--bar);border-radius:3px}
	#ov .opt{text-align:right;font-weight:800;font-variant-numeric:tabular-nums}
	#ov .why{grid-column:2 / -1;color:var(--muted);font-size:10.5px;margin-top:-2px;line-height:1.5}
	#ov .osum{margin-top:11px;padding-top:10px;border-top:1px solid var(--line);
	font-size:11px;color:#31465e;line-height:1.65}
	#ov .osum b{color:var(--accent)}
	#ov .ofoot{margin-top:9px;font-size:10px;color:var(--muted);line-height:1.5}
	#ov .oflag{margin-top:9px;background:#fdeeec;border-radius:7px;padding:7px 9px;
	font-size:10.5px;color:var(--bad);line-height:1.5}
	tbody tr{cursor:help}
	#tabs{display:flex;gap:6px;margin-top:20px}
	#tabs button{border:1px solid var(--line);background:#fff;color:var(--muted);
	font:inherit;font-size:13.5px;font-weight:700;padding:10px 20px;border-radius:11px;
	cursor:pointer;box-shadow:var(--shadow)}
	#tabs button.on{background:var(--accent);color:#fff;border-color:var(--accent)}
	.panel{display:none} .panel.on{display:block}

	.gsec{margin-top:20px}
	.gsec h3{margin:0 0 4px;font-size:16px;font-weight:800;letter-spacing:-.2px}
	.gsec .lead{color:var(--muted);font-size:13px;margin:0 0 14px;max-width:82ch;line-height:1.7}
	.facts{display:grid;grid-template-columns:repeat(3,1fr);gap:12px}
	@media(max-width:820px){.facts{grid-template-columns:1fr}}
	.fact{background:#fbfcfe;border:1px solid var(--line);border-radius:11px;padding:13px 15px}
	.fact b{display:block;font-size:11px;letter-spacing:.8px;text-transform:uppercase;
	color:var(--accent);margin-bottom:5px}
	.fact span{font-size:12.5px;color:#31465e;line-height:1.6}

	.pcard{border:1px solid var(--line);border-radius:12px;margin-bottom:12px;overflow:hidden}
	.phead{display:flex;align-items:center;gap:10px;padding:12px 15px;background:#fbfcfe;
	border-bottom:1px solid var(--line)}
	.ptag{background:var(--accent);color:#fff;font-size:11px;font-weight:800;
	width:24px;height:24px;border-radius:7px;display:flex;align-items:center;
	justify-content:center;flex:none}
	.phead b{font-size:13.5px} .phead span{font-size:11.5px;color:var(--muted)}
	.pcopy{margin-left:auto;background:#111827;color:#fff;border:0;border-radius:8px;
	padding:6px 13px;font:inherit;font-size:11.5px;font-weight:700;cursor:pointer}
	.pcopy:hover{background:#000}
	.pbody{padding:0;margin:0;background:#0f1420;color:#dbe4f0;font-size:11.5px;
	line-height:1.75;white-space:pre-wrap;word-break:break-word;
	font-family:ui-monospace,Menlo,Consolas,monospace;padding:14px 15px;max-height:290px;
	overflow:auto}
	.pbody em{color:#f0b429;font-style:normal;font-weight:700}

	.eng{display:grid;grid-template-columns:1fr 1fr;gap:14px;margin-top:6px}
	@media(max-width:820px){.eng{grid-template-columns:1fr}}
	.ecard{background:#fbfcfe;border:1px solid var(--line);border-radius:12px;padding:15px 16px}
	.ecard h4{margin:0 0 3px;font-size:14.5px;font-weight:800}
	.ecard .role{font-size:11px;letter-spacing:.6px;text-transform:uppercase;
	color:var(--accent);font-weight:700;margin-bottom:8px}
	.ecard p{margin:0;font-size:12.5px;color:var(--muted);line-height:1.7}
	.ecard ul{margin:9px 0 0;padding-left:17px;font-size:12.5px;color:#31465e;line-height:1.75}
	.proof{margin-top:14px;background:var(--accent-soft);border:1px solid #c6e6df;
	border-radius:11px;padding:14px 16px}
	.proof b{color:#0b5c51}
	.proof p{margin:0 0 8px;font-size:12.5px;color:#0b5c51;line-height:1.7}
	.boards{display:flex;flex-wrap:wrap;gap:5px;margin-top:9px}
	.boards span{font-size:10.5px;font-weight:700;background:#fff;border:1px solid #c6e6df;
	color:#0b5c51;border-radius:6px;padding:3px 8px;font-family:ui-monospace,monospace}
	.fails{width:100%;border-collapse:collapse;font-size:12.5px;margin-top:4px}
	.fails th{text-align:left;font-size:11px;padding-bottom:8px}
	.fails td{padding:9px 10px 9px 0;border-top:1px solid #f0f3f8;vertical-align:top;text-align:left}
	.fails td:first-child{font-weight:700;white-space:nowrap;color:var(--bad);width:200px}
	.terms{margin-top:20px;display:grid;grid-template-columns:1fr 1fr;gap:20px}
	@media(max-width:900px){.terms{grid-template-columns:1fr}}
	.prize{background:linear-gradient(135deg,#fffdf7 0%,#fdf4e3 100%);border-color:#f0dfba}
	.prize .amt{font-size:34px;font-weight:900;color:var(--anchor);letter-spacing:-1px;margin:4px 0 2px}
	.prize .amt small{font-size:13px;font-weight:700;color:#9a7420;letter-spacing:0}
	.prize p{font-size:13px;color:#6b5a36;margin:0 0 9px;line-height:1.7}
	.prize .tot{font-size:12.5px;font-weight:700;color:#9a7420;margin:0 0 10px}
	.prize .fine{font-size:11.5px;color:#8a7649;border-top:1px solid #f0dfba;padding-top:10px;margin-top:2px}
	.own p{font-size:13px;color:#31465e;margin:0 0 9px;line-height:1.7}
	.own .warn{background:#fdeeec;border:1px solid #f3d3ce;border-radius:9px;
	padding:11px 13px;font-size:12.5px;color:#8e2f27;line-height:1.65;margin-top:4px}
	.own .keep{background:var(--accent-soft);border:1px solid #c6e6df;border-radius:9px;
	padding:11px 13px;font-size:12.5px;color:#0b5c51;line-height:1.65}
	.vis{display:flex;gap:8px;margin-top:6px}
	.vis label{flex:1;margin:0;display:flex;gap:8px;align-items:flex-start;cursor:pointer;
	background:#fbfcfe;border:1px solid var(--line);border-radius:9px;padding:10px 11px;
	font-size:12px;font-weight:600;color:var(--ink);letter-spacing:0;text-transform:none}
	.vis label.on{border-color:var(--accent);background:var(--accent-soft)}
	.vis input{width:auto;margin:2px 0 0}
	.vis span{display:block;font-weight:500;color:var(--muted);font-size:11px;margin-top:2px}
	.chart{margin-top:20px}
	.mrow{display:grid;grid-template-columns:150px 1fr 132px;gap:12px;align-items:center;
	padding:9px 0;border-bottom:1px solid #f0f3f8}
	.mrow:last-child{border-bottom:0}
	.mname{font-size:13px;font-weight:700;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}
	.mname span{display:block;font-size:10.5px;color:var(--muted);font-weight:600}
	.mtrack{position:relative;height:22px;background:var(--bar-bg);border-radius:6px;overflow:visible}
	.mtrack .best{position:absolute;left:0;top:0;bottom:0;background:linear-gradient(90deg,#0f7b6c,#2aa694);
	border-radius:6px}
	.mtrack .mean{position:absolute;top:-3px;bottom:-3px;width:2px;background:#123;opacity:.55}
	.mmerge{font-size:9.5px;color:var(--accent);vertical-align:super;font-weight:800}
	.mtrack .lab{position:absolute;right:7px;top:0;line-height:22px;font-size:11.5px;
	font-variant-numeric:tabular-nums;
	font-weight:800;color:#fff;text-shadow:0 1px 2px rgba(0,0,0,.25)}
	.muse{display:flex;align-items:center;gap:7px;justify-content:flex-end}
	.muse .ub{height:8px;border-radius:4px;background:#9db4d6;min-width:3px}
	.muse .un{font-size:11.5px;color:var(--muted);font-weight:700;white-space:nowrap}
	.legend{display:flex;gap:14px;flex-wrap:wrap;margin-top:12px;font-size:11px;color:var(--muted)}
	.legend i{display:inline-block;width:10px;height:10px;border-radius:3px;margin-right:5px;vertical-align:-1px}
	.grid{display:grid;grid-template-columns:1fr 348px;gap:20px;align-items:start;margin-top:20px}
	/* A grid item defaults to min-width:auto, so the 1fr column refused to shrink below
	the table's min-width and pushed the submission card off-screen. */
	.grid > *{min-width:0}
	@media(max-width:960px){.grid{grid-template-columns:1fr}#langbar{position:static;margin-bottom:14px;width:max-content}#langnote{position:static;margin-bottom:8px}}
	.card{background:var(--panel);border:1px solid var(--line);border-radius:16px;
	padding:18px 20px;box-shadow:var(--shadow)}
	.card h2{margin:0 0 4px;font-size:13px;letter-spacing:1.4px;text-transform:uppercase;color:var(--muted)}
	.cnt{float:right;font-size:11.5px;color:var(--muted);letter-spacing:0}

	.scroll{overflow-x:auto;margin-top:12px}
	table{width:100%;border-collapse:collapse;font-size:13.5px;min-width:760px}
	th{color:var(--muted);font-weight:700;font-size:11px;letter-spacing:.5px;
	text-transform:uppercase;padding:0 9px 10px;border-bottom:2px solid var(--line);
	text-align:right;cursor:pointer;user-select:none;white-space:nowrap}
	th:nth-child(-n+3){text-align:left}
	th:hover{color:var(--accent)}
	th .ar{opacity:.32;margin-left:3px;font-size:9px}
	th.sorted{color:var(--accent)} th.sorted .ar{opacity:1}
	td{padding:11px 9px;border-bottom:1px solid #f0f3f8;text-align:right;
	font-variant-numeric:tabular-nums}
	td:nth-child(-n+3){text-align:left}
	tbody tr:hover{background:#fbfcfe}
	tr.anchor{background:var(--anchor-soft)}
	tr.anchor:hover{background:#fbf0dc}
	.sd{color:#8a8f98;font-size:10.5px;margin-left:3px;font-weight:500}
	.tag.w{background:#fff4e5;color:#9a5b00;border:1px solid #f0d9b5}
	tr.tier2{opacity:.62}
	.rk{width:58px;color:var(--muted);font-weight:700;white-space:nowrap}
	.rk.top{color:var(--accent);font-size:15px}
	.tot{font-variant-numeric:tabular-nums}
	.rk .rkscore{display:block;margin-top:2px;font-size:10.5px;font-weight:800;
	font-variant-numeric:tabular-nums;
	color:var(--ink);letter-spacing:0}
	.cid{font-family:ui-monospace,Menlo,Consolas,monospace;font-size:12.5px;font-weight:600}
	.skel{color:#93a1b5;font-size:11px;font-family:ui-monospace,monospace}
	.smiwrap{display:flex;align-items:center;gap:6px;max-width:250px}
	.smi2{color:#1c2a3d;font-size:12px;font-weight:600;
	font-family:ui-monospace,Menlo,Consolas,monospace;
	overflow:hidden;text-overflow:ellipsis;white-space:nowrap}
	.cp{flex:none;border:1px solid var(--line);background:#fff;border-radius:6px;
	width:22px;height:22px;line-height:1;cursor:pointer;color:var(--muted);
	font-size:11px;padding:0}
	.cp:hover{border-color:var(--accent);color:var(--accent);background:var(--accent-soft)}
	.cp.done{border-color:var(--accent);color:#fff;background:var(--accent)}
	.lock{color:#93a1b5;font-size:10.5px;margin-top:1px;display:block}
	#ov .osmi{margin-top:10px;padding:9px 10px;background:#f6f8fc;border:1px solid var(--line);
	border-radius:8px;font-family:ui-monospace,Menlo,monospace;font-size:10.5px;
	color:#31465e;line-height:1.5;word-break:break-all;position:relative}
	#ov .osmi .cp{position:absolute;top:6px;right:6px}
	#ov .osmi .d3{position:absolute;top:6px;right:32px}
	.d3{flex:none;border:1px solid var(--line);background:#fff;border-radius:6px;
	height:22px;padding:0 6px;line-height:1;cursor:pointer;color:var(--muted);
	font-size:10px;font-weight:700;letter-spacing:.02em}
	.d3:hover{border-color:var(--accent);color:var(--accent);background:var(--accent-soft)}
	/* the viewer is a modal, not a panel: a molecule you are turning over deserves the
	whole window, and the table underneath would only compete for the drag */
	#m3{position:fixed;inset:0;z-index:120;display:none;background:rgba(16,23,34,.55);
	backdrop-filter:blur(3px)}
	#m3.on{display:flex;align-items:center;justify-content:center}
	#m3 .box{background:#fff;border-radius:16px;width:min(720px,94vw);
	box-shadow:0 24px 70px rgba(12,18,28,.35);overflow:hidden}
	#m3 .hd{display:flex;align-items:center;gap:10px;padding:12px 14px;
	border-bottom:1px solid var(--line)}
	#m3 .hd b{font-size:13px;color:#16223a}
	#m3 .hd .f{font-family:ui-monospace,Menlo,monospace;font-size:11px;color:var(--muted)}
	#m3 .hd .x{margin-left:auto;border:0;background:none;font-size:20px;line-height:1;
	cursor:pointer;color:var(--muted);padding:0 4px}
	#m3 .stage{position:relative;height:min(430px,52vh);background:#0d1420}
	#m3 .stage canvas{display:block}
	#m3 .msg{position:absolute;inset:0;display:flex;align-items:center;justify-content:center;
	color:#93a6c0;font-size:12px}
	#m3 .ft{display:flex;align-items:center;gap:8px;padding:10px 14px;flex-wrap:wrap}
	#m3 .ft .sm{font-family:ui-monospace,Menlo,monospace;font-size:10.5px;color:#4a5d78;
	word-break:break-all;flex:1;min-width:0}
	#m3 .ft button{border:1px solid var(--line);background:#fff;border-radius:7px;
	padding:5px 10px;font-size:11px;cursor:pointer;color:#33465f}
	#m3 .ft button:hover{border-color:var(--accent);color:var(--accent)}
	#m3 .ft button.on{border-color:var(--accent);background:var(--accent);color:#fff}
	.who{color:var(--muted);font-size:12.5px}
	.hf-user{color:var(--accent);font-weight:700;text-decoration:none;white-space:nowrap}
	.hf-user:hover{text-decoration:underline}
	/* Long model identifiers wrapped onto four lines and made every row three times
	taller than it needed to be. Truncate; the full value is on the tooltip. */
	td:nth-child(3), td:nth-child(4){max-width:150px}
	td:nth-child(3) > , td:nth-child(4) > {display:block;max-width:150px;
	overflow:hidden;text-overflow:ellipsis;white-space:nowrap}
	td:nth-child(2){max-width:300px}
	.tag{display:inline-block;font-size:9.5px;font-weight:800;letter-spacing:.7px;
	padding:2px 7px;border-radius:5px;margin-left:6px;vertical-align:1px}
	.tag.a{background:#f6e2ba;color:var(--anchor)}
	.tag.r{background:#f7ded9;color:var(--bad)}
	.tot{font-weight:800;font-size:15.5px}
	.barwrap{display:flex;align-items:center;gap:8px;justify-content:flex-end}
	.bar{width:52px;height:6px;border-radius:4px;background:var(--bar-bg);overflow:hidden;flex:none}
	.bar i{display:block;height:100%;background:var(--bar);border-radius:4px}
	tr.anchor .bar i{background:var(--anchor)}

	label{display:block;font-size:11.5px;font-weight:700;color:var(--muted);
	margin:14px 0 5px;letter-spacing:.3px}
	input,textarea{width:100%;background:#fbfcfe;border:1px solid var(--line);border-radius:9px;
	color:var(--ink);padding:10px 12px;font:inherit;font-size:13.5px}
	input:focus,textarea:focus{outline:0;border-color:var(--accent);background:#fff;
	box-shadow:0 0 0 3px var(--accent-soft)}
	textarea{resize:vertical;min-height:58px}
	button.go{width:100%;margin-top:18px;background:var(--accent);color:#fff;border:0;
	border-radius:10px;padding:12px;font:inherit;font-weight:800;cursor:pointer;
	box-shadow:0 4px 12px rgba(15,123,108,.24)}
	button.go:hover{background:#0c6558} button.go:disabled{opacity:.5;cursor:default;box-shadow:none}
	.msg{margin-top:13px;font-size:12.5px;padding:11px 13px;border-radius:9px;display:none;line-height:1.55}
	.msg.ok{display:block;background:var(--accent-soft);color:#0b5c51;border:1px solid #c6e6df}
	.msg.err{display:block;background:#fdeeec;color:var(--bad);border:1px solid #f3d3ce}
	.note{color:var(--muted);font-size:11.5px;line-height:1.7;margin-top:16px;
	border-top:1px solid var(--line);padding-top:13px}
	.note b{color:#31465e}
	.xlink{display:inline-flex;align-items:center;gap:7px;border:1px solid var(--line);
	background:var(--card);border-radius:9px;padding:6px 12px;font-size:12.5px;
	color:var(--muted);text-decoration:none;margin:8px 0 0}
	.xlink:hover{border-color:var(--accent);color:var(--accent)}
	.xlink b{color:var(--ink);font-weight:600}
	.xlink em{font-style:normal;opacity:.75}
	</style>
	</head>
	<body>
	<div id="ov"></div>
	<div id="m3"><div class="box">
	<div class="hd"><b id="m3f"></b><span class="f" id="m3w"></span>
	<button class="x" id="m3x" aria-label="close">×</button></div>
	<div class="stage"><div id="m3v" style="width:100%;height:100%;position:relative"></div>
	<div class="msg" id="m3m"></div></div>
	<div class="ft"><span class="sm" id="m3s"></span>
	<button id="m3st" class="on" data-s="stick">Stick</button>
	<button id="m3sp" data-s="sphere">Space-fill</button>
	<button id="m3rt" class="on" title="spin">↻</button></div>
	</div></div>
	<div class="wrap">

	<header>
	<div id="langbar">
	<button data-lang="ko">한국어</button><button data-lang="en">English</button>
	</div>
	<div id="authbar"></div>
	<div id="langnote"></div>
	<div id="tally"></div>
	<div id="seasonbar"></div>
	<a class="xlink" id="xlink" href="https://huggingface.co/spaces/FINAL-Bench/open-materials-challenge" target="_blank" rel="noopener"></a>
	<a class="xlink" id="xlink2" href="https://huggingface.co/spaces/FINAL-Bench/leadboard" target="_blank" rel="noopener"></a>
	<div id="milestone" class="ms" hidden></div>
	<div id="cd"><span class="cdlab" id="cdlab"></span><span class="cdval" id="cdval"> </span></div>
	<p class="eyebrow">Open Discovery Challenge</p>
	<h1 id="seasonhead">#1  <em data-i18n="topic">Malaria</em></h1>
	<p class="concept" id="concept"></p>
	<p class="sub" data-i18n="tagline"></p>
	<div class="wts" id="wts"></div>
	</header>

	<section class="how">
	<h2 data-i18n="how_h">How it works</h2>
	<p class="why" id="why"></p>
	<div class="steps">
	<div class="step"><span class="n">1</span>
	<h3 data-i18n="s1_h"></h3><p data-i18n="s1_p"></p>
	<div class="models">
	<span>OpenAI</span><span>Claude</span><span>Gemini</span>
	<span>Qwen</span><span>KIMI</span><span>DeepSeek</span><span>…</span>
	</div>
	</div>
	<div class="step"><span class="n">2</span>
	<h3 data-i18n="s2_h"></h3><p data-i18n="s2_p"></p></div>
	<div class="step"><span class="n">3</span>
	<h3 data-i18n="s3_h"></h3><p data-i18n="s3_p"></p></div>
	</div>
	</section>

	<div id="tabs">
	<button data-panel="board" class="on" data-i18n="tab_board">Leaderboard</button>
	<button data-panel="models" data-i18n="tab_models">Model standings</button>
	<button data-panel="guide" data-i18n="tab_guide">Entrant guide</button>
	</div>

	<div class="panel on" id="p-board">
	<section class="terms">
	<div class="card prize">
	<h2 data-i18n="prize_h">Prize</h2>
	<div class="amt" id="prize_amt">$1,000 <small data-i18n="prize_unit">USD</small></div>
	<div class="tot" id="prize_total"></div>
	<p id="prize_body"></p>
	<div class="fine" id="prize_fine"></div>
	</div>
	<div class="card own">
	<h2 data-i18n="own_h">Your molecule stays yours</h2>
	<div class="keep" id="own_keep"></div>
	<p id="own_body" style="margin-top:10px"></p>
	<div class="warn" id="own_warn"></div>
	</div>
	</section>



	<div class="grid">
	<div class="card">
	<h2><span data-i18n="board">Leaderboard</span><span class="cnt" id="counts"></span></h2>
	<div class="scroll">
	<table>
	<thead><tr id="head"></tr></thead>
	<tbody id="rows"></tbody>
	</table>
	</div>
	<div class="pager" id="pager"></div>
	<div class="note" id="boardnote"></div>
	</div>

	<div class="card">
	<h2 data-i18n="submit">Submit</h2>
	<label data-i18n="l_struct"></label>
	<input id="structure" placeholder="CC1=NC2=NC(=NN2C(=C1)N...">
	<label data-i18n="l_name"></label>
	<input id="display_name">
	<label data-i18n="l_model"></label>
	<input id="model_name" placeholder="anthropic/claude-…, Qwen/…">
	<label data-i18n="l_why"></label>
	<textarea id="rationale"></textarea>
	<label data-i18n="l_vis"></label>
	<div class="vis">
	<label class="on" id="vis_priv"><input type="radio" name="vis" value="private" checked>
	<b data-i18n="vis_priv"></b></label>
	<label id="vis_pub"><input type="radio" name="vis" value="public">
	<b data-i18n="vis_pub"></b></label>
	</div>
	<button class="go" id="go" data-i18n="btn"></button>
	<div class="gate" id="gate" style="display:none"></div>
	<div class="msg" id="msg"></div>
	<div class="note" id="formnote"></div>
	</div>
	</div>
	</div>

	<div class="panel" id="p-models">
	<section class="card chart">
	<h2><span data-i18n="chart_h">Model standings</span><span class="cnt" id="mcounts"></span></h2>
	<p class="who" id="chart_sub" style="margin:2px 0 10px"></p>
	<div id="models"></div>
	<div class="legend" id="legend"></div>
	</section>
	</div>

	<div class="panel" id="p-guide">
	<!-- 시즌 소개 영상. 첫 화면(순위표)이 아니라 가이드 탭에 둔다 - 보러 온
	사람은 순위를 보러 오지 영상을 보러 오지 않는다. 가이드를 펼친 사람에게는
	맥락이 되므로 거기서 값을 한다. -->
	<div id="intro"></div>
	<section class="card gsec">
	<h3 data-i18n="g1_h"></h3>
	<p class="lead" id="g1_lead"></p>
	<div class="facts">
	<div class="fact"><b data-i18n="g1_a_t"></b><span data-i18n="g1_a"></span></div>
	<div class="fact"><b data-i18n="g1_b_t"></b><span data-i18n="g1_b"></span></div>
	<div class="fact"><b data-i18n="g1_c_t"></b><span data-i18n="g1_c"></span></div>
	</div>
	</section>

	<section class="card gsec">
	<h3 data-i18n="g2_h"></h3>
	<p class="lead" id="g2_lead"></p>
	<div id="prompts"></div>
	</section>

	<section class="card gsec">
	<h3 data-i18n="ge_h"></h3>
	<p class="lead" id="ge_lead"></p>
	<div class="eng">
	<div class="ecard">
	<div class="role" data-i18n="ge_p_role"></div>
	<h4>PharmaOS</h4>
	<p data-i18n="ge_p_body"></p>
	<ul id="ge_p_list"></ul>
	</div>
	<div class="ecard">
	<div class="role" data-i18n="ge_c_role"></div>
	<h4>CellOS</h4>
	<p data-i18n="ge_c_body"></p>
	<ul id="ge_c_list"></ul>
	</div>
	</div>
	<div class="proof">
	<p id="ge_proof"></p>
	<div class="boards" id="ge_boards"></div>
	<p id="ge_caveat" style="margin-top:10px;font-size:11.5px;opacity:.85"></p>
	</div>
	</section>

	<section class="card gsec">
	<h3 data-i18n="g3_h"></h3>
	<p class="lead" id="g3_lead"></p>
	<table class="fails"><tbody id="fails"></tbody></table>
	</section>

	<section class="card gsec">
	<h3 data-i18n="g4_h"></h3>
	<p class="lead" id="g4_lead"></p>
	</section>
	</div>
	</div>

	<script>
	const T = {
	ko:{
	xlink:`🔋 <b>Open Materials Challenge</b> <em>— 전고체 배터리 신소재를 찾는 자매 대회</em> ↗`,
	xlink2:`🎯 <b>LEADBOARD</b> <em>— 신약 예측 도구를 분야별로 재는 시험대</em> ↗`,
	topic:"말라리아", board:"순위표", submit:"제출", btn:"제출하기",
	concept:"<b>AI가 발견한 말라리아 신약 후보 물질</b>의 검증 및 평가",
	tagline:"어떤 AI로 찾아낸 후보든, 같은 기준으로 계산 검증하고 점수를 매깁니다. 표적은 말라리아 원충이 의존하는 효소 PfDHODH이며, 사람의 같은 효소(DHODH)는 건드리지 않아야 합니다.",
	how_h:"참여 방법",
	why:"<b>매년 약 59만 7천 명이 말라리아로 죽습니다. 그중 4분의 3이 다섯 살이 되기 전의 아이들입니다</b>(WHO 세계 말라리아 보고서 2024, 2023년 추정). 약이 없어서가 아닙니다. 환자가 가난해서 약을 만들 이유가 시장에 없기 때문입니다. 바로 그래서, 이익이 아니라 뜻으로 움직이는 사람들이 실제로 차이를 만들 수 있는 자리입니다.<br><br>AI는 이미 신약 후보를 쏟아내고 있습니다. 막힌 곳은 발견이 아니라 <b>그 후보가 정말 쓸 만한지 가려낼 검증 수단</b>입니다. 모델은 그럴듯한 분자를 얼마든지 그려내지만, 그것이 기생충을 죽이는지·사람에게 해로운지·만들 수는 있는지는 답하지 못합니다. 이 챌린지는 그 검증기를 공개합니다 — <b>AI가 발견한 후보를 받아, 같은 잣대로 계산 검증하고 순위를 매깁니다.</b>",
	s1_h:"1. 원하는 AI로 후보를 설계합니다",
	s1_p:"OpenAI · Claude · Gemini · Qwen · KIMI · DeepSeek 등 어떤 모델이든, 어떤 하네스든 자유입니다. 직접 설계해도 됩니다. 말라리아 원충 효소 PfDHODH를 막을 저분자를 찾으세요.",
	s2_h:"2. 분자 구조식을 제출합니다",
	s2_p:"SMILES 또는 InChI로 입력합니다. 제출 즉시 구조 검사(반응성·PAINS·중복 등)를 거칩니다. 분자식은 이성질체가 너무 많아 받지 않습니다.",
	s3_h:"3. 자동 채점 후 순위가 매겨집니다",
	s3_p:"비드래프트 PharmaOS와 CellOS가 약효·표적 결합·선택성·독성·신규성·합성 난이도를 계산해 100점 만점으로 채점하고, 고득점 순으로 줄을 세웁니다. 기준물질이 함께 표시되어 자기 점수의 의미를 바로 확인할 수 있습니다.",
	ov_axes:{activity:"약효",binding:"결합",selectivity:"선택성",admet:"ADMET",novelty:"신규성",synthesis:"합성"},
	ov_why:{
	activity:d=>`전세포 예측 pAct(하한) ${d.pAct_q10 ?? "–"}`,
	binding:d=>`pIC50 ${d.pIC50 ?? "–"} · 리간드효율 ${d.LE ?? "–"}`,
	selectivity:d=>`사람 대비 ${d.fold ?? "–"}배 · 표적결합 ${d.target_engagement ?? "–"}`,
	admet:d=>`바람직성 기하평균 ${d.geometric_mean ?? "–"}`,
	novelty:d=>`기존 물질과 최대 유사도 ${d.max_tanimoto ?? "–"}`,
	synthesis:d=>`합성난이도 SA ${d.sa_score ?? "–"} (1 쉬움 ~ 10 어려움)`,
	},
	ov_pred:"예측치", ov_pf:"말라리아 효소", ov_hs:"사람 효소", ov_sel:"선택도",
	private_note:"제출자가 비공개를 선택했습니다", copy_smiles:"분자식 복사",
	intro_credit:"영상 제작해주신 카카오톡 @리카 님에게 감사드립니다.",
	tally_label:"누적 제출", daily_cap:"계정당 하루 30건까지 제출할 수 있습니다 (한국시간 자정 초기화).",
	season_soon:"준비중", season_notopen:"이 시즌은 아직 접수를 받지 않습니다. 채점기 검증이 끝나면 공지와 함께 엽니다.",
	cd_label:"시즌 #1 마감까지", cd_day:"일", cd_over_label:"시즌 #1 마감",
	cd_over:"마감되었습니다", view_3d:"3D 입체 구조로 보기",
	v3_loading:"입체 구조 생성 중\u2026", v3_atoms:"원자",
	v3_failed:"입체 구조를 만들지 못했습니다",
	private_full:"제출자가 비공개를 선택했습니다. 후보 ID와 골격 해시로만 식별됩니다.",
	reasons:{
	parse: r=>"구조를 해석할 수 없습니다 (SMILES 또는 InChI로 제출하세요)",
	covalent: r=>`공유결합 warhead 검출 (${r.arg}) — Season 1은 비공유 트랙입니다`,
	mw: r=>`분자량 ${r.arg} > ${r.limit}`,
	heavy: r=>`무거운 원자 ${r.arg} > ${r.limit}`,
	pains: r=>`PAINS 구조 (${r.arg})`,
	duplicate: r=>"이미 제출된 구조입니다",
	ames: r=>`변이원성(Ames) ${r.arg} > ${r.limit}`,
	solubility: r=>`극단적 불용성 (logS ${r.arg} < ${r.limit})`,
	},
	ov_none:"채점 근거가 기록되지 않았습니다.",
	ov_foot:"모두 계산 예측값입니다. 실측이 아니며 실제 효능·안전성을 뜻하지 않습니다.",
	tab_board:"순위표",tab_models:"모델 성과", tab_guide:"참여 가이드",
	ge_h:"무엇이 채점하는가",
	ge_lead:"제출된 분자는 VIDRAFT의 두 시스템이 함께 평가합니다. 하나는 분자가 표적에 어떻게 작용하는지를 보고, 다른 하나는 그것이 살아 있는 세포와 몸에서 무엇을 뜻하는지를 봅니다.",
	ge_p_role:"분자 · 표적", ge_c_role:"세포 · 개체",
	ge_p_body:"분자가 표적 단백질에 실제로 결합하는지, 얼마나 세게 붙는지, 그리고 그 결합이 크기로 산 것인지 설계로 얻은 것인지를 판정합니다.",
	ge_p_list:["말라리아 효소와 사람 효소에 각각 도킹해 결합 예측","분자 크기 대비 결합 효율 — 무겁게 만들어 점수를 사는 것을 차단","기존 항말라리아 화학공간과의 구조적 거리","합성 접근성"],
	ge_c_body:"결합만으로는 약이 되지 않습니다. 기생충이 실제로 죽는지, 사람에게 해롭지 않은지, 몸 안에서 견디는지를 봅니다.",
	ge_c_list:["전세포 항말라리아 활성 — 기생충이 죽는가","흡수·분포·대사·배설과 독성 프로파일","사람 효소 회피 — 면역억제 부작용 차단","불확실한 예측은 낮게 채점 — 확신할 수 있는 후보가 우대됨"],
	ge_proof:"<b>이 채점을 왜 믿을 수 있는가.</b> 우리 예측 모델은 공개 벤치마크 <b>Polaris Hub의 16개 부문에서 1위</b>로 기록되어 있습니다. 흡수·분포·대사·독성·효능·인산화효소 선택성 전 영역에 걸쳐 있으며, 가장 최근은 <b>MDR1-MDCK 유출비</b>(2026-08-11, 상관계수 0.802 · 2위 0.725)입니다. 아래가 그 16개 부문이며, Polaris에서 쓰는 이름 그대로 적었으니 직접 대조하실 수 있습니다.",
	ge_caveat:"⚠️ 16개 부문이 모두 Polaris에 실재하는 벤치마크임은 확인했습니다. 다만 Polaris Hub는 순위(placement)를 공개 API로 제공하지 않아 등수 자체는 외부에서 자동 검증할 수 없습니다.<br>그리고 이 대회의 채점이 정직한지는 더 간단히 확인하실 수 있습니다 — <b>승인된 약과 효과 없는 물질을 순위표에 함께 올려두었습니다.</b> 임상 후보가 상단에, 카페인과 이부프로펜이 바닥에 있는지 보시면 됩니다.",
	g1_h:"무엇을 만들어야 하나",
	g1_lead:"말라리아 원충은 살아남기 위해 <b>PfDHODH</b>라는 효소에 의존합니다. 이 효소를 막으면 원충이 죽습니다. 문제는 사람에게도 같은 계열의 효소가 있다는 것입니다.",
	g1_a_t:"막아야 할 것", g1_a:"PfDHODH — 말라리아 원충의 효소. 원충이 생존에 의존합니다.",
	g1_b_t:"건드리면 안 되는 것", g1_b:"사람 DHODH — 같은 계열. 막으면 치료가 아니라 면역억제 부작용이 됩니다.",
	g1_c_t:"넘어야 할 관문", g1_c:"원충은 적혈구 안에 삽니다. 적혈구막과 원충막, 두 겹을 통과해야 표적에 닿습니다.",
	g2_h:"AI에게 그대로 붙여 넣을 프롬프트",
	g2_lead:"전략이 다른 다섯 가지입니다. <b>어떤 모델이든 상관없습니다</b> — OpenAI, Claude, Gemini, Qwen, KIMI, DeepSeek, 오픈소스 무엇이든. 복사 버튼을 누르고 쓰시면 됩니다.<br><b>노란 글씨 부분은 반드시 자기 것으로 바꾸십시오.</b> 그대로 쓰면 다른 참가자와 같은 분자가 나오고, 먼저 낸 쪽만 등록되며 나머지는 중복으로 반려됩니다.",
	g3_h:"자주 겪는 반려 사유",
	g3_lead:"제출 즉시 구조 검사를 하므로, 아래에 걸리면 순위표에 오르지 못하고 바로 되돌아옵니다.",
	fails:[
	["기지 물질의 유사체","신규성 점수가 0에 가깝습니다. 기준물질 자체가 신규성 0점이라, 그 유사체도 같은 0을 물려받습니다. 실측으로 유사체 하나가 10점 만점에 0.96을 받았습니다."],
	["PAINS 구조","여러 표적에 무차별로 걸리는 구조입니다. 자동 반려됩니다."],
	["분자량 {MW} 초과","자동 반려됩니다. 무거운 분자로 결합 점수를 올리는 것을 막기 위한 상한입니다."],
	["분자식 제출","C20H25N3O4 같은 분자식은 이성질체가 너무 많아 평가가 불가능합니다. SMILES 또는 InChI로 내십시오."],
	["같은 구조 재제출","이미 등록된 구조와 같으면 반려됩니다. 먼저 낸 분에게 귀속됩니다."],
	],
	g4_h:"점수는 어떻게 나뉘나",
	g4_lead:"{WEIGHTS}<br><br><b>기준을 감추지 않는 이유가 있습니다.</b> 무엇이 점수를 받는지 알면 참가자가 실제로 더 나은 분자를 만듭니다. 우리가 원하는 건 그것입니다.<br><br>몇 가지 정책만 미리 알려드립니다. <b>신규성은 효력에 곱해집니다</b> — 새롭기만 하고 듣지 않으면 0점입니다. <b>ADMET·신규성·합성은 후보성에 비례합니다</b> — 아무 효과 없는 안전한 분자는 성취가 아닙니다. <b>불확실한 예측은 낮게 채점됩니다</b> — 우리 도구가 확신하지 못하는 후보는 그만큼 깎입니다.<br><br>순위표에서 각 행에 마우스를 올리면 <b>축별 점수와 그 근거 수치</b>가 나옵니다. 그대로 복사해 프롬프트 E에 넣으시면 됩니다.",
	prize_h:"상금", prize_unit:"USD",
	prize_total_label:(amt,n)=>`시즌 ${n}개 누적 총 상금 $${amt}`,
	prize_body:"각 시즌이 끝날 때 <b>순위표 1위에게 상금을 드립니다.</b> 첫 시즌(#1 말라리아)은 <b>2026년 9월 30일</b> 마감이며 상금은 미화 1,000달러입니다.<br><br>이 돈은 여러분이 쓴 시간과 토큰에 대한 대가가 되기에는 턱없이 부족합니다. 그렇게 계산할 생각도 없습니다. <b>이것은 “당신이 한 일에 값이 있었다”고 말하는 방식입니다.</b><br><br>소외질환 연구가 힘든 이유는 아무도 고맙다고 하지 않기 때문입니다. 논문도 잘 안 실리고, 투자도 안 붙고, 아무도 보지 않습니다. 이 대회는 최소한 누가 무엇을 기여했는지 기록으로 남기고, 시즌마다 한 번 감사를 표합니다.",
	prize_fine:"시즌마다 대상 질병이 바뀝니다. · 상금은 미화(USD) 기준이며 지급 방법은 수상자와 협의하여 정합니다. · <b>후원사가 확보되면 상금 규모는 상향될 수 있습니다.</b> · 수상자는 Space 커뮤니티 탭에 공지합니다. · 동점 시 먼저 제출한 분이 우선합니다. · 법령상 지급이 불가능한 경우는 제외될 수 있습니다.",
	own_h:"제출한 분자는 여러분의 것입니다",
	own_keep:"<b>소유권은 전적으로 제출자에게 있습니다.</b> VIDRAFT는 채점과 순위표 표시에 필요한 범위에서만 사용하며, 특허·소유권을 가져가지 않고 제3자에게 제공하지 않으며 자사 파이프라인에 투입하지 않습니다.",
	own_body:"공개 여부도 제출자가 정합니다. <b>비공개</b>를 선택하면 순위표에는 후보 ID·골격 해시·분자량 구간·점수만 표시되고 구조는 나오지 않습니다. <b>공개</b>를 선택하면 전체 구조가 표시되어 다른 참가자가 보고 배울 수 있습니다.",
	own_warn:"⚠️ <b>두 가지를 분명히 말씀드립니다.</b><br>① 비공개는 <b>다른 참가자와 대중에게</b> 공개하지 않는다는 뜻입니다. 채점하려면 구조가 필요하므로 VIDRAFT 시스템에는 저장되며, 채점 외 목적으로 쓰지 않습니다.<br>② <b>공개를 선택하면 특허 신규성을 잃을 수 있습니다.</b> 구조를 공개하는 순간 공지(disclosure)가 되어 이후 그 물질로 특허를 받기 어려워질 수 있습니다. 상업적 활용을 염두에 두셨다면 <b>비공개를 선택하고 출원을 먼저 하시기 바랍니다.</b>",
	l_vis:"공개 여부", vis_priv:"🔒 비공개 (기본)", vis_pub:"🔓 전체 구조 공개",
	chart_h:"AI 모델별 성과",
	chart_sub:"어느 모델이 <b>가장 좋은 후보</b>를 냈는지(막대)와 <b>얼마나 쓰이는지</b>(오른쪽)를 함께 봅니다. 많이 쓰인다고 잘하는 것은 아니므로 따로 표시합니다.",
	chart_empty:"채점된 제출이 쌓이면 모델별 성과가 여기에 표시됩니다.",
	lg_best:"최고 점수", lg_mean:"평균", lg_use:"제출 수",
	mcounts:(m,n)=>"모델 "+m+" · 제출 "+n,
	signin:"Hugging Face로 로그인", signout:"로그아웃",
	gate:"제출하려면 <b>Hugging Face 로그인</b>이 필요합니다. 제출자 계정이 순위표에 함께 표시되며, 이는 다른 사람 이름으로 올리는 것을 막고 모델별 집계를 신뢰할 수 있게 합니다.",
	entrants:"명 참가",
	l_struct:"분자 구조식 (SMILES 또는 InChI)", l_name:"표시 ID (이름·소속·닉네임)",
	l_model:"사용 모델명 (선택)", l_why:"설계 근거 (선택)",
	cols:{rank:"#",cand:"후보",user:"제출자",who:"모델",date:"제출일",activity:"약효",binding:"결합",
	selectivity:"선택성",admet:"ADMET",novelty:"신규",synthesis:"합성",total:"총점"},
	counts:(a,b)=>`제출 ${a} · 기준물질 ${b}`,
	prange:(a,b,n)=>`${a.toLocaleString()}–${b.toLocaleString()} / 전체 ${n.toLocaleString()}`,
	empty:"아직 채점된 제출이 없습니다.", loading:"불러오는 중…",
	anchor:"기준", relegated:"강등", ref:"기준물질", reactive:"반응성",
	boardnote:"<b>기준물질(노란 행)은 점수를 받되 등수를 갖지 않습니다.</b> 척도를 눈으로 확인하시라고 넣었습니다.<br>구조는 전체 공개하지 않습니다 — 골격 해시와 분자량 구간만 표시되며 원본은 비공개로 보관됩니다.<br>점수는 <b>계산 기반 후보 평가</b>이며 실제 효능·안전성이나 승인약과의 우열을 뜻하지 않습니다.<br>열 제목을 눌러 정렬할 수 있습니다.",
	formnote:"분자식(C20H25N3O4 등)은 받지 않습니다 — 이성질체가 너무 많아 평가가 불가능합니다.<br>제출 즉시 구조 검사를 거치고, 채점은 GPU 작업 대기열에서 처리됩니다(수 분 소요).",
	need:"구조와 표시 ID는 필수입니다.", fail:"요청 실패: ", rejected:"제출이 거부되었습니다",
	busy:"저장소가 혼잡해 접수를 확정하지 못했습니다. 잠시 뒤 그대로 다시 제출하세요 - 혹시 먼저 기록됐다면 중복으로 안내됩니다.",
	queued:(id,n,note)=>`접수되었습니다 · ${id} · 대기 ${n}건. ${note}`,
	auto:"브라우저 설정에서 자동 선택", manual:"직접 선택함",
	},
	en:{
	xlink:`🔋 <b>Open Materials Challenge</b> <em>— the sister challenge, for battery materials</em> ↗`,
	xlink2:`🎯 <b>LEADBOARD</b> <em>— the benchmark for drug prediction tools</em> ↗`,
	topic:"Malaria", board:"Leaderboard", submit:"Submit", btn:"Submit entry",
	concept:"Verifying and evaluating <b>AI-discovered malaria drug candidates</b>",
	tagline:"However you found the candidate, it is checked computationally against the same rubric and scored. The target is PfDHODH, an enzyme the malaria parasite depends on; the human counterpart must be left alone.",
	how_h:"How to take part",
	why:"<b>Malaria kills about 597,000 people a year, and roughly three quarters of them are children who never reach five</b> (WHO World Malaria Report 2024, 2023 estimates). Not for want of chemistry - for want of a market, because the patients are poor. Which is exactly where people working from conviction rather than return can still change the outcome.<br><br>AI already produces drug candidates in volume. The bottleneck is no longer discovery but <b>the means to check whether a candidate is any good</b>. A model will draw plausible molecules all day; it cannot tell you whether they kill the parasite, harm the patient, or can be made at all. This challenge publishes that check — <b>bring what your AI found, and it is verified computationally and ranked on the same scale as everyone else's.</b>",
	s1_h:"1. Design a candidate with any AI",
	s1_p:"OpenAI, Claude, Gemini, Qwen, KIMI, DeepSeek — any model, any harness, or by hand. The goal is a small molecule that blocks PfDHODH, an enzyme the malaria parasite depends on.",
	s2_h:"2. Submit the structure",
	s2_p:"Enter it as SMILES or InChI. Every entry is structure-checked on arrival for reactivity, PAINS and duplicates. Molecular formulas are not accepted — too many isomers.",
	s3_h:"3. It is scored and ranked automatically",
	s3_p:"VIDRAFT's PharmaOS and CellOS compute activity, target binding, selectivity, toxicity, novelty and synthetic accessibility out of 100, and the table orders entries by score. Reference compounds sit in the same table so you can read what your number means.",
	ov_axes:{activity:"Activity",binding:"Binding",selectivity:"Selectivity",admet:"ADMET",novelty:"Novelty",synthesis:"Synthesis"},
	ov_why:{
	activity:d=>`whole-cell pAct, lower bound ${d.pAct_q10 ?? "–"}`,
	binding:d=>`pIC50 ${d.pIC50 ?? "–"} · ligand efficiency ${d.LE ?? "–"}`,
	selectivity:d=>`${d.fold ?? "–"}x over human · engagement ${d.target_engagement ?? "–"}`,
	admet:d=>`desirability, geometric mean ${d.geometric_mean ?? "–"}`,
	novelty:d=>`nearest known compound ${d.max_tanimoto ?? "–"}`,
	synthesis:d=>`SA score ${d.sa_score ?? "–"} (1 easy - 10 hard)`,
	},
	ov_pred:"Predicted", ov_pf:"parasite enzyme", ov_hs:"human enzyme", ov_sel:"selectivity",
	private_note:"structure withheld by the entrant", copy_smiles:"Copy SMILES",
	tally_label:"entries", daily_cap:"Up to 30 entries per account per day, resetting at midnight KST.",
	season_soon:"soon", season_notopen:"This season is not taking entries yet. It opens once the scorer has been checked, and we will say so.",
	cd_label:"Season #1 closes in", cd_day:"Day", cd_over_label:"Season #1 closed",
	cd_over:"closed", view_3d:"View in 3D",
	v3_loading:"building conformer\u2026", v3_atoms:"atoms",
	v3_failed:"could not build a 3D conformer",
	private_full:"The entrant chose to keep this structure private. It is identified only by its candidate ID and skeleton hash.",
	reasons:{
	parse: r=>"Structure could not be parsed (submit SMILES or InChI)",
	covalent: r=>`Covalent warhead detected (${r.arg}) — Season 1 is a non-covalent track`,
	mw: r=>`Molecular weight ${r.arg} > ${r.limit}`,
	heavy: r=>`Heavy atoms ${r.arg} > ${r.limit}`,
	pains: r=>`PAINS motif (${r.arg})`,
	duplicate: r=>"This structure has already been entered",
	ames: r=>`Predicted mutagenicity (Ames) ${r.arg} > ${r.limit}`,
	solubility: r=>`Extreme insolubility (logS ${r.arg} < ${r.limit})`,
	},
	ov_none:"No scoring detail was recorded for this entry.",
	ov_foot:"All values are computed predictions, not measurements, and are not claims about real efficacy or safety.",
	tab_board:"Leaderboard",tab_models:"Model standings", tab_guide:"Entrant guide",
	ge_h:"What does the scoring",
	ge_lead:"Every entry is assessed by two VIDRAFT systems working together. One asks how the molecule behaves against the target; the other asks what that means in a living cell and a whole body.",
	ge_p_role:"molecule · target", ge_c_role:"cell · organism",
	ge_p_body:"Whether the molecule actually binds the target protein, how tightly, and whether that affinity was designed or simply bought with bulk.",
	ge_p_list:["Docking against the parasite enzyme and the human one","Binding efficiency relative to size — so mass cannot buy points","Structural distance from known antimalarial chemical space","Synthetic accessibility"],
	ge_c_body:"Binding is not a drug. Whether the parasite dies, whether the patient is harmed, and whether the compound survives a body at all.",
	ge_c_list:["Whole-cell antimalarial activity — does the parasite die","Absorption, distribution, metabolism, excretion and toxicity","Avoiding the human enzyme — no immunosuppression","Uncertain predictions score lower — confidence is rewarded"],
	ge_proof:"<b>Why trust the scoring.</b> Our predictive models hold <b>first place across 16 tracks of the public benchmark Polaris Hub</b>, spanning absorption, distribution, metabolism, toxicity, potency and kinase selectivity. The most recent is <b>MDR1-MDCK efflux ratio</b> (11 Aug 2026, correlation 0.802 against 0.725 for second). All sixteen are named below under the slugs Polaris uses, so you can look each one up.",
	ge_caveat:"⚠️ All sixteen were checked to exist as Polaris benchmarks. Polaris does not expose placements through a public API, so the rankings themselves cannot be verified automatically from outside.<br>Whether <em>this</em> contest scores honestly is easier to check — <b>approved drugs and inert compounds sit in the same table as the entries.</b> See whether the clinical candidate lands at the top and caffeine and ibuprofen land at the bottom.",
	g1_h:"What you are designing",
	g1_lead:"The malaria parasite depends on an enzyme called <b>PfDHODH</b> to survive. Block it and the parasite dies. The complication is that we have a close relative of that enzyme ourselves.",
	g1_a_t:"Block this", g1_a:"PfDHODH — the parasite's enzyme. It cannot survive without it.",
	g1_b_t:"Leave this alone", g1_b:"Human DHODH — the homologue. Inhibiting it gives immunosuppression, not a cure.",
	g1_c_t:"Get past this", g1_c:"The parasite lives inside a red blood cell. Two membranes stand between your compound and the target.",
	g2_h:"Prompts to paste into your model",
	g2_lead:"Five, each with a different strategy. <b>Any model works</b> — OpenAI, Claude, Gemini, Qwen, KIMI, DeepSeek, open weights, whatever you use. Copy and go.<br><b>Change the highlighted part.</b> Used verbatim, these produce the same molecules for everyone; the first submission is registered and the rest come back as duplicates.",
	g3_h:"Why entries get rejected",
	g3_lead:"Structures are checked on arrival, so anything below comes straight back rather than reaching the table.",
	fails:[
	["Analogue of a known drug","Novelty lands near zero. The reference compound scores zero there itself, and an analogue inherits it — one tested analogue scored 0.96 out of 10."],
	["PAINS motif","Structures that hit many targets indiscriminately. Rejected automatically."],
	["Molecular weight over {MW}","Rejected. The cap stops binding scores being bought with sheer mass."],
	["A molecular formula","C20H25N3O4 and the like have too many isomers to evaluate. Submit SMILES or InChI."],
	["A structure already entered","Duplicates are rejected and credited to whoever submitted first."],
	],
	g4_h:"How the points divide",
	g4_lead:"{WEIGHTS}<br><br><b>The rubric is published on purpose.</b> An entrant who knows what earns points produces better molecules than one who is guessing, and better molecules are the entire objective.<br><br>A few policies worth knowing up front. <b>Novelty is multiplied by potency</b> — new and inert is worth nothing. <b>ADMET, novelty and synthesis scale with how much of a candidate the molecule is</b> — a perfectly safe compound that does nothing has achieved nothing. <b>Uncertain predictions score lower</b> — where our tools are unsure, you are marked down accordingly.<br><br>Hover any row on the leaderboard to see <b>every axis and the numbers behind it</b>. Copy that into prompt E.",
	prize_h:"Prize", prize_unit:"USD",
	prize_total_label:(amt,n)=>`$${amt} in total across ${n} seasons`,
	prize_body:"When a season closes, <b>the entry at the top of the table receives a prize.</b> Season #1 (Malaria) closes on <b>30 September 2026</b> and carries USD 1,000.<br><br>This does not come close to paying for the time and tokens you spent, and it is not meant to. <b>It is a way of saying that what you did had worth.</b><br><br>Neglected-disease work is thankless by construction: the papers are hard to place, the funding is not there, and mostly nobody looks. This challenge at least records who contributed what, and says thank you once a season.",
	prize_fine:"Each season targets a different disease. · The prize is denominated in USD; the method of payment is agreed with the recipient. · <b>Should sponsors come on board, the amount may increase.</b> · Winners are announced in the Space community tab. · Ties go to whoever submitted first. · Payment may be withheld where law forbids it.",
	own_h:"Your molecule stays yours",
	own_keep:"<b>Ownership remains entirely with the entrant.</b> VIDRAFT uses a submission only to score it and to display it on the table. We take no patent or ownership interest, pass nothing to third parties, and put nothing into our own pipeline.",
	own_body:"You also decide who sees it. Choose <b>private</b> and the table shows only a candidate ID, a skeleton hash, a molecular-weight band and the scores. Choose <b>public</b> and the full structure is shown, so other entrants can learn from it.",
	own_warn:"⚠️ <b>Two things stated plainly.</b><br>1. Private means hidden from other entrants and the public. Scoring needs the structure, so it is stored on VIDRAFT systems and used for nothing else.<br>2. <b>Making a structure public can cost you patentability.</b> Publication is disclosure, and disclosure can bar a later patent on that compound. If you have any commercial intent, <b>keep it private and file first.</b>",
	l_vis:"Visibility", vis_priv:"🔒 Private (default)", vis_pub:"🔓 Publish full structure",
	chart_h:"Model standings",
	chart_sub:"Which model produced the <b>best candidate</b> (bar) alongside <b>how much it gets used</b> (right). Popularity is not quality, so the two are shown separately.",
	chart_empty:"Model standings appear here once scored entries accumulate.",
	lg_best:"best score", lg_mean:"mean", lg_use:"entries",
	mcounts:(m,n)=>m+" models · "+n+" entries",
	signin:"Sign in with Hugging Face", signout:"Sign out",
	gate:"Submitting requires a <b>Hugging Face sign-in</b>. Your account is shown next to your entry, which stops anyone posting under someone else's name and keeps the per-model chart trustworthy.",
	entrants:"entrants",
	l_struct:"Structure (SMILES or InChI)", l_name:"Display ID (name, affiliation or handle)",
	l_model:"Model used (optional)", l_why:"Design rationale (optional)",
	cols:{rank:"#",cand:"Candidate",user:"Entrant",who:"Model",date:"Submitted",activity:"Activity",binding:"Binding",
	selectivity:"Select.",admet:"ADMET",novelty:"Novelty",synthesis:"Synth.",total:"Total"},
	counts:(a,b)=>`${a} entries · ${b} references`,
	prange:(a,b,n)=>`${a.toLocaleString()}–${b.toLocaleString()} of ${n.toLocaleString()}`,
	empty:"No scored entries yet.", loading:"Loading…",
	anchor:"REF", relegated:"RELEG.", ref:"reference", reactive:"reactive",
	boardnote:"<b>Reference compounds (amber rows) are scored but never ranked.</b> They are there so you can see the scale.<br>Structures are not published in full — only a skeleton hash and a molecular-weight band; the original is held privately.<br>Scores are a <b>computational assessment of candidates</b>. They are not a claim about real efficacy or safety, nor a comparison against approved drugs.<br>Click a column header to sort.",
	formnote:"Molecular formulas (C20H25N3O4 and the like) are not accepted — too many isomers to evaluate.<br>Entries are structure-checked on submission; scoring runs on a GPU queue and takes a few minutes.",
	need:"Structure and display ID are required.", fail:"Request failed: ", rejected:"Entry rejected",
	busy:"The ledger was too busy to confirm this entry. Resubmit the same candidate in a moment - if it did land, you will be told it is a duplicate.",
	queued:(id,n,note)=>`Accepted · ${id} · ${n} in queue. ${note}`,
	auto:"detected from your browser", manual:"chosen by you",
	}
	};

	// The visitor's own setting decides; the toggle can still override it.
	let LANG = (function(){
	const n = (navigator.languages && navigator.languages[0]) \|\| navigator.language \|\| "en";
	return String(n).toLowerCase().startsWith("ko") ? "ko" : "en";
	})();
	let LANG_AUTO = true;

	const COLS = ["rank","cand","user","who","date","activity","binding","selectivity","admet","novelty","synthesis","total"];
	const AX = ["activity","binding","selectivity","admet","novelty","synthesis"];
	let DATA = null, sortKey = "total", sortDir = -1;
	// Large seasons are drawn one page at a time rather than all at once.
	const PAGE_SIZE = 500;
	let page = 0;

	const $ = s => document.querySelector(s);

	// Which season the whole page is showing. Kept in the URL so a link to a season is a
	// link to that season, and remembered so a return visit lands where the reader left off.
	let SEASON = (function(){
	const u = new URLSearchParams(location.search).get("season");
	const v = u \|\| localStorage.getItem("odc_season") \|\| "1";
	return parseInt(v, 10) \|\| 1;
	})();
	let SEASONS = null;
	function seasonInfo(){
	return (SEASONS \|\| []).find(s => s.number === SEASON) \|\| null;
	}
	function qs(){ return "?season=" + SEASON; }
	const f1 = v => (v==null\|\|v==="") ? "–" : (+v).toFixed(1);
	// totals carry three decimals; the per-axis columns stay at one, where the extra digits
	// would be width without information
	const f3 = v => (v==null\|\|v==="") ? "–" : (+v).toFixed(3);

	// ---------------------------------------------------------------- season copy
	// Only what actually differs between seasons. Everything else lives in T and is shared,
	// so a new season is a block of writing rather than an edit to the page.
	const ST = {
	ko: {
	1: {
	topic:"말라리아",
	concept:"<b>AI가 발견한 말라리아 신약 후보 물질</b>의 검증 및 평가",
	tagline:"어떤 AI로 찾아낸 후보든, 같은 기준으로 계산 검증하고 점수를 매깁니다. 표적은 말라리아 원충이 의존하는 효소 PfDHODH이며, 사람의 같은 효소(DHODH)는 건드리지 않아야 합니다.",
	s1_p:"OpenAI · Claude · Gemini · Qwen · KIMI · DeepSeek 등 어떤 모델이든, 어떤 하네스든 자유입니다. 직접 설계해도 됩니다. 말라리아 원충 효소 PfDHODH를 막을 저분자를 찾으세요.",
	ov_pf:"말라리아 효소", ov_hs:"사람 효소",
	g1_lead:"말라리아 원충은 살아남기 위해 <b>PfDHODH</b>라는 효소에 의존합니다. 이 효소를 막으면 원충이 죽습니다. 문제는 사람에게도 같은 계열의 효소가 있다는 것입니다.",
	g1_a:"PfDHODH — 말라리아 원충의 효소. 원충이 생존에 의존합니다.",
	g1_b:"사람 DHODH — 같은 계열. 막으면 치료가 아니라 면역억제 부작용이 됩니다.",
	cd_label:"시즌 #1 마감까지", cd_over_label:"시즌 #1 마감",
	prize_amt:"$1,000",
	prize_body:"각 시즌이 끝날 때 <b>순위표 1위에게 상금을 드립니다.</b> 시즌 #1(말라리아)은 <b>2026년 9월 30일</b> 마감이며 상금은 미화 1,000달러입니다.<br><br>이 돈은 여러분이 쓴 시간과 토큰에 대한 대가가 되기에는 턱없이 부족합니다. 그렇게 계산할 생각도 없습니다. <b>이것은 “당신이 한 일에 값이 있었다”고 말하는 방식입니다.</b><br><br>소외질환 연구가 힘든 이유는 아무도 고맙다고 하지 않기 때문입니다. 논문도 잘 안 실리고, 투자도 안 붙고, 아무도 보지 않습니다. 이 대회는 최소한 누가 무엇을 기여했는지 기록으로 남기고, 시즌마다 한 번 감사를 표합니다."
	},
	2: {
	topic:"결핵",
	concept:"<b>AI가 발견한 결핵 신약 후보 물질</b>의 검증 및 평가",
	tagline:"어떤 AI로 찾아낸 후보든, 같은 기준으로 계산 검증하고 점수를 매깁니다. 표적은 결핵균이 세포벽을 만드는 데 쓰는 효소 InhA이며, 사람의 같은 화학을 담당하는 효소(FASN 에노일환원효소 영역)는 건드리지 않아야 합니다.",
	why:"<b>결핵은 한 해 약 125만 명의 목숨을 가져갑니다. 단일 감염병으로는 세계 최다입니다</b>(WHO 세계 결핵 보고서 2024). 치료제는 있습니다. 다만 <b>6개월을 매일 먹어야 하고</b>, 그마저도 듣지 않는 내성균이 계속 늘고 있습니다. 다제내성 결핵 환자는 1년 넘게 약을 먹고도 절반 가까이 낫지 못합니다.<br><br>새 항결핵제가 드문 이유는 과학이 막혀서가 아닙니다. 환자 대부분이 가난한 나라에 있어 시장이 성립하지 않기 때문입니다. 40년 넘게 신약이 하나도 나오지 않다가 2012년에야 베다퀼린이 승인됐습니다.<br><br>시즌 #2는 그 자리를 겨냥합니다. <b>AI가 그려낸 후보를 받아, 같은 잣대로 계산 검증하고 순위를 매깁니다.</b>",
	s1_p:"OpenAI · Claude · Gemini · Qwen · KIMI · DeepSeek 등 어떤 모델이든, 어떤 하네스든 자유입니다. 직접 설계해도 됩니다. 결핵균 효소 InhA를 막을 저분자를 찾으세요.",
	ov_pf:"결핵균 효소", ov_hs:"사람 효소",
	g1_lead:"결핵균은 세포벽의 지방산을 만들 때 <b>InhA</b>라는 효소를 씁니다. 결핵 표준 치료제인 이소니아지드가 실제로 막는 효소가 이것입니다. 문제는 사람에게도 같은 화학을 하는 효소가 있다는 것입니다.",
	g1_a:"InhA — 결핵균의 에노일환원효소. 이소니아지드·에티오나미드가 작용하는 자리입니다.",
	g1_b:"사람 FASN의 에노일환원효소 영역 — 같은 화학. 막으면 지방산 합성이 함께 멈춥니다.",
	g1_c:"결핵균은 밀랍 같은 마이콜산 세포벽에 싸여 있습니다. 웬만한 세균보다 훨씬 덜 투과되고, 배출 펌프도 활발합니다.",
	cd_label:"시즌 #2 마감까지", cd_over_label:"시즌 #2 마감",
	prize_amt:"$2,000",
	prize_body:"각 시즌이 끝날 때 <b>순위표 1위에게 상금을 드립니다.</b> 시즌 #2(결핵)는 <b>2026년 10월 31일</b> 마감이며 상금은 미화 2,000달러입니다.<br><br>이 돈은 여러분이 쓴 시간과 토큰에 대한 대가가 되기에는 턱없이 부족합니다. 그렇게 계산할 생각도 없습니다. <b>이것은 “당신이 한 일에 값이 있었다”고 말하는 방식입니다.</b><br><br>소외질환 연구가 힘든 이유는 아무도 고맙다고 하지 않기 때문입니다. 논문도 잘 안 실리고, 투자도 안 붙고, 아무도 보지 않습니다. 이 대회는 최소한 누가 무엇을 기여했는지 기록으로 남기고, 시즌마다 한 번 감사를 표합니다."
	},
	3: {
	topic:"샤가스병",
	concept:"<b>AI가 발견한 샤가스병 신약 후보 물질</b>의 검증 및 평가",
	tagline:"어떤 AI로 찾아낸 후보든, 같은 기준으로 계산 검증하고 점수를 매깁니다. 표적은 샤가스병 원충이 세포막 스테롤을 만드는 데 쓰는 효소 CYP51이며, 사람의 같은 효소(CYP51A1)는 건드리지 않아야 합니다.",
	why:"<b>샤가스병은 중남미를 중심으로 약 600만 명이 앓고 있습니다</b>(WHO). 대부분 오랜 세월 증상 없이 지내다가 심장이나 소화기가 서서히 망가집니다.<br><br>치료제는 <b>60년 된 두 가지뿐</b>입니다. 벤즈니다졸과 니푸르티목스 모두 부작용이 심해 상당수 환자가 복용을 중단하고, 만성기에는 효과도 불확실합니다.<br><br>새 약이 나오지 않는 이유는 과학이 막혀서가 아닙니다. 환자 대부분이 가난한 지역에 있어 시장이 성립하지 않기 때문입니다. WHO가 지정한 소외열대질환의 대표 사례입니다.",
	s1_p:"OpenAI · Claude · Gemini · Qwen · KIMI · DeepSeek 등 어떤 모델이든, 어떤 하네스든 자유입니다. 직접 설계해도 됩니다. 샤가스병 원충의 효소 CYP51을 막을 저분자를 찾으세요.",
	ov_pf:"원충 효소", ov_hs:"사람 효소",
	g1_lead:"샤가스병 원충은 세포막에 필요한 스테롤을 만들 때 <b>CYP51</b>이라는 효소를 씁니다. 이 효소를 막으면 원충이 살아남지 못합니다. 문제는 사람에게도 <b>같은 이름의 같은 효소</b>가 있다는 것입니다.",
	g1_a:"T. cruzi CYP51 — 원충의 스테롤 14α-탈메틸화효소. 아졸계 약물이 실제로 작용하는 자리입니다.",
	g1_b:"사람 CYP51A1 — 같은 효소. 아졸계 항진균제의 부작용이 여기서 나옵니다.",
	g1_c:"원충은 숙주 세포 안에, 특히 심근 세포 안에 아마스티고트 형태로 삽니다. 숙주 세포막과 원충막을 차례로 통과해야 표적에 닿습니다.",
	cd_label:"시즌 #3 마감까지", cd_over_label:"시즌 #3 마감",
	prize_amt:"$1,000",
	prize_body:"각 시즌이 끝날 때 <b>순위표 1위에게 상금을 드립니다.</b> 시즌 #3(샤가스병)은 <b>2026년 11월 30일</b> 마감이며 상금은 미화 1,000달러입니다.<br><br>이 돈은 여러분이 쓴 시간과 토큰에 대한 대가가 되기에는 턱없이 부족합니다. 그렇게 계산할 생각도 없습니다. <b>이것은 “당신이 한 일에 값이 있었다”고 말하는 방식입니다.</b><br><br>소외질환 연구가 힘든 이유는 아무도 고맙다고 하지 않기 때문입니다. 논문도 잘 안 실리고, 투자도 안 붙고, 아무도 보지 않습니다. 이 대회는 최소한 누가 무엇을 기여했는지 기록으로 남기고, 시즌마다 한 번 감사를 표합니다."
	},
	4: {
	topic:"비마약성 진통",
	concept:"<b>AI가 발견한 비마약성 진통제 후보 물질</b>의 검증 및 평가",
	tagline:"어떤 AI로 찾아낸 후보든, 같은 기준으로 계산 검증하고 점수를 매깁니다. 표적은 통증 신호를 나르는 나트륨 채널 Nav1.7이며, 심장 박동을 조절하는 hERG 채널은 건드리지 않아야 합니다.",
	why:"<b>WHO는 2023년 보고서의 제목을 「통증 속에 남겨진 사람들」이라고 붙였습니다.</b><br><br>같은 약이 세상의 한쪽에서는 넘쳐서 사람을 죽이고, 다른 한쪽에서는 없어서 사람을 고통 속에 죽게 합니다.<br><br><b>넘치는 쪽.</b> WHO 추산으로 2019년 약물로 인한 사망 약 60만 명 가운데 80%가 오피오이드와 관련되어 있습니다. 2021년 약 6,000만 명이 오피오이드를 사용했고, 의존 치료가 필요한 사람 중 실제로 치료받는 사람은 10%에 미치지 못합니다.<br><br><b>없는 쪽.</b> 같은 WHO 보고서는 고소득국과 저소득국의 모르핀 사용량 차이가 <b>5배에서 63배</b>에 이른다고 적었습니다. 가장 부유한 10% 국가가 유통되는 모르핀의 90%를 씁니다. 나머지 사람들은 수술 뒤에도, 말기 암에도 진통제 없이 견딥니다.<br><br>두 문제의 답은 하나입니다. <b>의존성 없는 진통제.</b> 그것이 있으면 넘치는 쪽은 덜 죽고, 없는 쪽은 마약 규제에 묶이지 않고 쓸 수 있습니다.<br><br>Nav1.7은 그 답에 가장 가까이 간 표적입니다. 이 채널이 작동하지 않는 유전자를 가진 사람들은 <b>통증을 느끼지 않으면서 다른 감각은 정상</b>입니다. 동물이 아니라 사람이 직접 증명해 준 표적입니다.<br><br>그런데도 아직 약이 없습니다. 어려움은 표적이 아니라 <b>구분</b>에 있습니다. 몸에는 비슷한 나트륨 채널이 여럿 있고, 심장의 hERG 채널을 함께 막으면 부정맥으로 사람이 죽습니다. 여러 후보가 그 이유로 개발이 중단됐습니다.<br><br>이 시즌이 묻는 것은 하나입니다. <b>통증 채널만 골라 막을 수 있는가.</b>",
	s1_p:"OpenAI · Claude · Gemini · Qwen · KIMI · DeepSeek 등 어떤 모델이든, 어떤 하네스든 자유입니다. 직접 설계해도 됩니다. 통증 신호를 나르는 나트륨 채널 Nav1.7을 막되 심장 채널은 건드리지 않는 저분자를 찾으세요.",
	ov_pf:"통증 채널", ov_hs:"심장 채널",
	g1_lead:"통증 신호는 신경에서 <b>나트륨 채널</b>을 통해 전달됩니다. 그중 <b>Nav1.7</b>은 통증 신경에 집중적으로 있어 이것만 막으면 통증만 줄일 수 있습니다. 문제는 몸에 비슷한 채널이 여럿 있고, 특히 <b>심장 채널을 함께 막으면 위험하다</b>는 것입니다.",
	g1_a:"Nav1.7 VSD4 — 도메인 IV 전압센서. 이 계열 저해제가 실제로 붙는 자리입니다. 채널 전체가 아니라 이 구간을 씁니다.",
	g1_b:"hERG 공극 — 심장 재분극을 담당하는 칼륨 채널. 여기를 막으면 부정맥 위험이 생깁니다. 네 개 소단위가 모여 약물이 들어가는 공간을 만들기 때문에 <b>4량체로</b> 계산합니다.",
	g1_c:"진통제는 통증이 생기는 곳까지 닿아야 하므로 대체로 작고 가볍습니다. 이 시즌의 크기 한도가 이전 시즌보다 낮은 이유입니다.",
	cd_label:"시즌 #4 마감까지", cd_over_label:"시즌 #4 마감",
	prize_amt:"$1,000",
	prize_body:"각 시즌이 끝날 때 <b>순위표 1위에게 상금을 드립니다.</b> 시즌 #4(비마약성 진통)는 <b>2027년 1월 31일</b> 마감이며 상금은 미화 1,000달러입니다.<br><br>이 돈은 여러분이 쓴 시간과 토큰에 대한 대가가 되기에는 턱없이 부족합니다. 그렇게 계산할 생각도 없습니다. <b>이것은 “당신이 한 일에 값이 있었다”고 말하는 방식입니다.</b><br><br>통증은 흔한 문제지만, 오피오이드를 대신할 약을 찾는 일은 오래 막혀 있었습니다. 이 대회는 최소한 누가 무엇을 기여했는지 기록으로 남기고, 시즌마다 한 번 감사를 표합니다."
	}
	},
	en: {
	1: {
	topic:"Malaria",
	concept:"<b>Verifying and scoring malaria drug candidates discovered by AI</b>",
	tagline:"However you found the candidate, it is checked computationally against the same rubric and scored. The target is PfDHODH, an enzyme the malaria parasite depends on; the human counterpart must be left alone.",
	s1_p:"OpenAI, Claude, Gemini, Qwen, KIMI, DeepSeek - any model, any harness, or by hand. The goal is a small molecule that blocks PfDHODH, an enzyme the malaria parasite depends on.",
	ov_pf:"parasite enzyme", ov_hs:"human enzyme",
	g1_lead:"The malaria parasite depends on an enzyme called <b>PfDHODH</b> to survive. Block it and the parasite dies. The difficulty is that humans carry an enzyme of the same family.",
	g1_a:"PfDHODH - the parasite's enzyme, which it cannot live without.",
	g1_b:"Human DHODH - same family. Blocking it is immunosuppression, not treatment.",
	cd_label:"Season #1 closes in", cd_over_label:"Season #1 closed",
	prize_amt:"$1,000",
	prize_body:"When a season closes, <b>the entry at the top of the table receives a prize.</b> Season #1 (Malaria) closes on <b>30 September 2026</b> and carries USD 1,000.<br><br>This does not come close to paying for the time and tokens you spent, and it is not meant to. <b>It is a way of saying that what you did had worth.</b><br><br>Neglected-disease work is thankless by construction: the papers are hard to place, the funding is not there, and mostly nobody looks. This challenge at least records who contributed what, and says thank you once a season."
	},
	2: {
	topic:"Tuberculosis",
	concept:"<b>Verifying and scoring tuberculosis drug candidates discovered by AI</b>",
	tagline:"However you found the candidate, it is checked computationally against the same rubric and scored. The target is InhA, the enzyme M. tuberculosis uses to build its cell wall; the human enzyme that does the same chemistry must be left alone.",
	why:"<b>Tuberculosis kills about 1.25 million people a year - more than any other single infection</b> (WHO Global TB Report 2024). Treatment exists. It also takes <b>six months of daily doses</b>, and resistant strains that shrug it off keep spreading. Patients with multidrug-resistant TB take drugs for over a year and close to half of them still are not cured.<br><br>New tuberculosis drugs are rare not because the science is stuck but because most patients are poor and there is no market. Forty years passed without a single new one before bedaquiline was approved in 2012.<br><br>Season #2 aims at that gap. <b>Bring what your AI found; it is verified computationally and ranked on the same scale as everyone else's.</b>",
	s1_p:"OpenAI, Claude, Gemini, Qwen, KIMI, DeepSeek - any model, any harness, or by hand. The goal is a small molecule that blocks InhA, an enzyme M. tuberculosis depends on.",
	ov_pf:"bacterial enzyme", ov_hs:"human enzyme",
	g1_lead:"M. tuberculosis uses an enzyme called <b>InhA</b> to build the fatty acids in its cell wall. It is what isoniazid, the front-line tuberculosis drug, actually blocks. The difficulty is that humans run the same chemistry.",
	g1_a:"InhA - the bacterium's enoyl reductase, where isoniazid and ethionamide act.",
	g1_b:"The enoyl-reductase domain of human FASN - same chemistry. Blocking it stops our own fatty-acid synthesis.",
	g1_c:"M. tuberculosis is wrapped in a waxy mycolic-acid wall, far less permeable than most bacteria, and it effluxes actively.",
	cd_label:"Season #2 closes in", cd_over_label:"Season #2 closed",
	prize_amt:"$2,000",
	prize_body:"When a season closes, <b>the entry at the top of the table receives a prize.</b> Season #2 (Tuberculosis) closes on <b>31 October 2026</b> and carries USD 2,000.<br><br>This does not come close to paying for the time and tokens you spent, and it is not meant to. <b>It is a way of saying that what you did had worth.</b><br><br>Neglected-disease work is thankless by construction: the papers are hard to place, the funding is not there, and mostly nobody looks. This challenge at least records who contributed what, and says thank you once a season."
	},
	3: {
	topic:"Chagas disease",
	concept:"<b>Verifying and scoring Chagas disease drug candidates discovered by AI</b>",
	tagline:"However you found the candidate, it is checked computationally against the same rubric and scored. The target is CYP51, the enzyme T. cruzi uses to build its membrane sterols; the human enzyme of the same name must be left alone.",
	why:"<b>Chagas disease affects around 6 million people, mostly in Latin America</b> (WHO). Many carry it for decades without symptoms while the heart or gut is slowly damaged.<br><br>There are <b>two drugs, both sixty years old</b>. Benznidazole and nifurtimox are hard enough to tolerate that many patients stop taking them, and their effect in the chronic stage is uncertain.<br><br>No new drug has arrived, not because the science is stuck but because the patients are poor and there is no market. It is the archetype of a WHO neglected tropical disease.",
	s1_p:"OpenAI, Claude, Gemini, Qwen, KIMI, DeepSeek - any model, any harness, or by hand. The goal is a small molecule that blocks CYP51, an enzyme T. cruzi depends on.",
	ov_pf:"parasite enzyme", ov_hs:"human enzyme",
	g1_lead:"T. cruzi uses an enzyme called <b>CYP51</b> to make the sterols its membranes need. Block it and the parasite cannot survive. The difficulty is that humans carry <b>an enzyme of the same name doing the same job</b>.",
	g1_a:"T. cruzi CYP51 - the parasite's sterol 14a-demethylase, where the azole drugs act.",
	g1_b:"Human CYP51A1 - the same enzyme. Azole antifungal side effects come from inhibiting it.",
	g1_c:"The parasite persists inside host cells as an amastigote, most importantly in cardiac muscle. Your compound has to cross the host cell membrane and then the parasite's.",
	cd_label:"Season #3 closes in", cd_over_label:"Season #3 closed",
	prize_amt:"$1,000",
	prize_body:"When a season closes, <b>the entry at the top of the table receives a prize.</b> Season #3 (Chagas disease) closes on <b>30 November 2026</b> and carries USD 1,000.<br><br>This does not come close to paying for the time and tokens you spent, and it is not meant to. <b>It is a way of saying that what you did had worth.</b><br><br>Neglected-disease work is thankless by construction: the papers are hard to place, the funding is not there, and mostly nobody looks. This challenge at least records who contributed what, and says thank you once a season."
	},
	4: {
	topic:"Non-opioid analgesia",
	concept:"<b>Verifying and scoring non-opioid analgesic candidates discovered by AI</b>",
	tagline:"However you found the candidate, it is checked computationally against the same rubric and scored. The target is Nav1.7, the sodium channel that carries pain signals; the cardiac hERG channel must be left alone.",
	why:"<b>WHO titled its 2023 report <i>Left behind in pain</i>.</b><br><br>The same class of drug kills people where it is abundant and leaves people to die in pain where it is absent.<br><br><b>Where there is too much.</b> WHO estimates that of roughly 600,000 deaths attributable to drug use in 2019, about 80% involved opioids. Around 60 million people used opioids in 2021, and fewer than one in ten of those who need treatment for dependence receive it.<br><br><b>Where there is none.</b> The same WHO report records a <b>5- to 63-fold</b> difference in morphine consumption between high-income and lower-income countries. The wealthiest 10% of countries account for 90% of the morphine distributed. Everyone else goes without - after surgery, and in terminal cancer.<br><br>Both problems have one answer. <b>An analgesic that does not create dependence.</b> Where there is excess, fewer people die; where there is none, it can be supplied without narcotic control.<br><br>Nav1.7 is the closest thing to that answer. People carrying loss-of-function variants of this channel <b>feel no pain while their other senses stay intact</b> - a target validated in humans rather than in animals.<br><br>And yet there is still no drug. The difficulty is not the target but <b>telling it apart</b>. The body carries several similar sodium channels, and a compound that also blocks the cardiac hERG channel can kill by arrhythmia. Several programmes stopped for exactly that reason.<br><br>This season asks one question. <b>Can you block the pain channel and only the pain channel?</b>",
	s1_p:"OpenAI, Claude, Gemini, Qwen, KIMI, DeepSeek - any model, any harness, or by hand. The goal is a small molecule that blocks Nav1.7, the sodium channel carrying pain signals, while leaving the cardiac channel alone.",
	ov_pf:"pain channel", ov_hs:"cardiac channel",
	g1_lead:"Pain signals travel along nerves through <b>sodium channels</b>. <b>Nav1.7</b> sits mainly in pain-sensing neurons, so blocking it should reduce pain and little else. The difficulty is that several similar channels exist, and <b>blocking the cardiac one is dangerous</b>.",
	g1_a:"Nav1.7 VSD4 - the domain IV voltage sensor, where this inhibitor class actually binds. The season docks this domain rather than the whole channel.",
	g1_b:"hERG pore - the potassium channel behind cardiac repolarisation. Blocking it carries arrhythmia risk. Four subunits together form the cavity a drug occupies, so it is modelled as a <b>tetramer</b>.",
	g1_c:"An analgesic has to reach where the pain is, so this chemistry runs small and light. That is why this season's size limits are lower than earlier ones.",
	cd_label:"Season #4 closes in", cd_over_label:"Season #4 closed",
	prize_amt:"$1,000",
	prize_body:"When a season closes, <b>the entry at the top of the table receives a prize.</b> Season #4 (Non-opioid analgesia) closes on <b>31 January 2027</b> and carries USD 1,000.<br><br>It is nowhere near payment for the time and tokens you spent, and it is not meant as payment. <b>It is a way of saying the work was worth something.</b><br><br>Pain is ordinary, but finding something to put in place of opioids has been stuck for a long time. This contest at least records who contributed what, and says thank you once a season."
	}
	}
	};

	// season copy wins over the shared strings; anything a season does not override is shared
	function t(){ return Object.assign({}, T[LANG], (ST[LANG] \|\| {})[SEASON] \|\| {}); }

	const submittedDate = e => {
	if(e.is_anchor \|\| !e.submitted_at) return "–";
	const locale = LANG === "ko" ? "ko-KR" : "en-CA";
	return new Intl.DateTimeFormat(locale, {
	timeZone:"Asia/Seoul", year:"numeric", month:"2-digit", day:"2-digit"
	}).format(new Date(Number(e.submitted_at) * 1000));
	};

	// Seasons can carry an intro clip. It is written into the page only for the season it
	// belongs to - emptied rather than hidden - so a reader on another season never fetches
	// the file. Muted and inline because autoplay with sound is blocked everywhere; the clip
	// has no audio track, so nothing is lost.
	const SEASON_INTRO = {2: "assets/season2-intro.mp4"};

	function renderIntro(){
	const src = SEASON_INTRO[SEASON], box = $("#intro");
	// clearing the marker as well as the markup: leaving it set made a return to this
	// season look like "already playing" and the slot stayed empty
	if(!src){ box.innerHTML = ""; delete box.dataset.src; return; }
	const cred = t().intro_credit \|\| "";
	if(box.dataset.src === src && box.querySelector("video")){
	// the clip is already playing; only the wording can have changed, and rewriting the
	// whole block would restart the video every time the language is switched
	const c = box.querySelector(".credit");
	if(c) c.textContent = cred;
	return;
	}
	box.dataset.src = src;
	box.innerHTML = `<video src="${src}" autoplay loop muted playsinline preload="metadata"></video>`
	+ (cred ? `<div class="credit">${cred}</div>` : "");
	}

	// Cumulative submissions per season. Its own timer, ten minutes apart: the board itself
	// reloads every twenty seconds and this number does not move that fast.
	let TALLY = null;

	async function loadTally(){
	if(!SEASONS) return;
	try{
	const rs = await Promise.all(SEASONS.map(x =>
	fetch("api/queue?season=" + x.number).then(r => r.json())));
	TALLY = SEASONS.map((x, i) => ({n: x.number, total: rs[i].total}))
	.sort((a, b) => b.n - a.n);
	renderTally();
	}catch(_){ /* leave the previous figure up rather than blanking it */ }
	}

	function renderTally(){
	if(!TALLY) return;
	const d = t();
	$("#tally").innerHTML = TALLY.map(x =>
	`<div class="t"><b>${x.total.toLocaleString()}</b>`
	+ `<span>#${x.n} ${d.tally_label}</span></div>`).join("");
	}

	function renderSeasonBar(){
	if(!SEASONS) return;
	const d = t();
	// newest season first: the one people are entering now should be the one they reach first
	$("#seasonbar").innerHTML = SEASONS.slice().sort((a,b)=>b.number-a.number).map(s => {
	const nm = (ST[LANG] && ST[LANG][s.number] && ST[LANG][s.number].topic) \|\| s.topic;
	// a season that is not taking entries says so on the button, so nobody clicks
	// through and writes out a molecule before finding out
	const tag = s.open ? "" : `<span class="st">${d.season_soon}</span>`;
	return `<button data-season="${s.number}" class="${s.number===SEASON?"on":""}">`
	+ `#${s.number} ${nm}${tag}</button>`;
	}).join("");
	document.querySelectorAll("#seasonbar button").forEach(b =>
	b.onclick = () => setSeason(parseInt(b.dataset.season,10)));
	}

	function setSeason(n){
	if(n === SEASON) return;
	SEASON = n;
	page = 0; // a new season starts at its own first page
	localStorage.setItem("odc_season", String(n));
	// the season belongs in the URL: a link to a season should open on that season
	const u = new URL(location.href); u.searchParams.set("season", String(n));
	history.replaceState(null, "", u);
	DATA = null; MODELS = {models:[],totals:{models:0,submissions:0}};
	$("#rows").innerHTML = "";
	applyLang(); load();
	}

	function applyLang(){
	const d = t();
	document.documentElement.lang = LANG;
	{ const x = $("#xlink"); if(x && d.xlink) x.innerHTML = d.xlink;
	const x2 = $("#xlink2"); if(x2 && d.xlink2) x2.innerHTML = d.xlink2; }
	document.querySelectorAll("[data-i18n]").forEach(el=>{
	const v = d[el.dataset.i18n]; if(v) el.textContent = v;
	});
	$("#concept").innerHTML = d.concept;
	["ge_lead","ge_proof","ge_caveat"].forEach(k => { const el=$("#"+k); if(el) el.innerHTML = d[k]; });
	["ge_p_list","ge_c_list"].forEach(k => { const el=$("#"+k);
	if(el) el.innerHTML = (d[k]\|\|[]).map(x => `<li>${x}</li>`).join(""); });
	const gb = $("#ge_boards");
	if(gb) gb.innerHTML = BOARDS.map(b => `<span>${b}</span>`).join("");
	// the rubric and the size cap are stated by the page but owned by the scorer, so they
	// are substituted from the season rather than written into the copy pack. Two of the
	// three seasons were showing season 1's numbers before this.
	["g1_lead","g2_lead","g3_lead","g4_lead"].forEach(k => { const el=$("#"+k); if(el) el.innerHTML = fillFacts(d[k]); });
	renderPrompts(); renderFails();
	$("#prize_body").innerHTML = d.prize_body;
	$("#prize_fine").innerHTML = d.prize_fine;
	$("#own_keep").innerHTML = d.own_keep;
	$("#own_body").innerHTML = d.own_body;
	$("#own_warn").innerHTML = d.own_warn;
	$("#why").innerHTML = d.why;
	$("#boardnote").innerHTML = d.boardnote;
	$("#formnote").innerHTML = d.formnote + (d.daily_cap ? "<br><b>" + d.daily_cap + "</b>" : "");
	$("#display_name").placeholder = LANG==="ko" ? "공개 순위표에 표시됩니다" : "shown on the public table";
	$("#rationale").placeholder = LANG==="ko" ? "왜 이 구조인지 간단히" : "why this structure, briefly";
	document.querySelectorAll("#langbar button").forEach(b=>b.classList.toggle("on", b.dataset.lang===LANG));
	$("#langnote").textContent = LANG_AUTO ? d.auto : d.manual;
	const si = seasonInfo();
	if(si){
	$("#seasonhead").innerHTML = `#${si.number}  <em>${d.topic}</em>`;
	document.title = `Open Discovery Challenge #${si.number} ${d.topic}`;
	}
	if(d.prize_amt) $("#prize_amt").firstChild.nodeValue = d.prize_amt + " ";
	// 누적 총 상금은 시즌 목록에서 더한다. 손으로 적으면 시즌이 하나 늘 때마다 틀린다 -
	// 부문 한도를 산문으로 적었다가 550 이 750 이 된 뒤에도 그대로 남아 있던 적이 있다.
	{ const el = $("#prize_total");
	if(el && SEASONS){
	const tot = SEASONS.reduce((a,s)=>a+(s.prize_usd\|\|0),0);
	el.textContent = d.prize_total_label
	? d.prize_total_label(tot.toLocaleString(), SEASONS.length) : "";
	} }
	renderSeasonBar();
	renderIntro();
	renderTally();
	renderAuth();
	tickCountdown();
	if(DATA) render();
	renderModels(MODELS);
	}
	function setLang(l, auto){ LANG = (l==="ko")?"ko":"en"; if(!auto) LANG_AUTO=false; applyLang(); }
	document.querySelectorAll("#langbar button").forEach(b=>b.onclick=()=>setLang(b.dataset.lang,false));

	function sortVal(e, k){
	if(k==="rank") return e.rank ?? 1e9; // unranked rows sink when sorting by rank
	if(k==="cand") return String(e.candidate_id\|\|"").toLowerCase();
	if(k==="user") return String(e.hf_user\|\|e.display_name\|\|"").toLowerCase();
	if(k==="who") return String(e.model_name\|\|"").toLowerCase();
	if(k==="date") return e.submitted_at ?? 0;
	if(k==="total") return e.total ?? -1;
	return (e.axes\|\|{})[k] ?? -1;
	}

	function esc(s){
	return String(s ?? "").replace(/[&<>"']/g, c=>({
	"&":"&", "<":"<", ">":">", '"':""", "'":"'"
	})[c]);
	}

	function hfProfile(user){
	if(!user) return "";
	const label = esc(user);
	const url = `https://huggingface.co/${encodeURIComponent(user)}`;
	return `<a class="hf-user" href="${url}" target="_blank" rel="noopener noreferrer"`
	+ ` title="Hugging Face: ${label}">🤗 ${label}</a>`;
	}

	function renderPager(total, pages){
	const host = $("#pager"), d = t();
	if(pages <= 1){ host.innerHTML = ""; return; }
	const from = page * PAGE_SIZE + 1;
	const to = Math.min(total, (page + 1) * PAGE_SIZE);

	// Every page number, once there are few enough to read; otherwise the ends, the
	// current neighbourhood, and gaps for the rest.
	let nums = [];
	if(pages <= 9){ for(let i=0;i<pages;i++) nums.push(i); }
	else {
	const near = [page-1, page, page+1].filter(i => i>0 && i<pages-1);
	nums = [0, ...near, pages-1];
	nums = [...new Set(nums)].sort((a,b)=>a-b);
	}
	let out = `<button ${page===0?"disabled":""} data-p="${page-1}">‹</button>`;
	let prev = -1;
	for(const i of nums){
	if(i - prev > 1) out += `<span class="gap">…</span>`;
	out += `<button class="${i===page?"on":""}" data-p="${i}">${i+1}</button>`;
	prev = i;
	}
	out += `<button ${page>=pages-1?"disabled":""} data-p="${page+1}">›</button>`;
	out += `<span class="pinfo">${d.prange(from, to, total)}</span>`;
	host.innerHTML = out;

	host.querySelectorAll("button[data-p]").forEach(b => b.onclick = () => {
	if(b.disabled) return;
	page = parseInt(b.dataset.p, 10);
	render();
	// Land at the top of the table, not wherever the previous page left the scroll.
	const c = document.querySelector(".card .scroll");
	if(c) window.scrollTo({top: c.getBoundingClientRect().top + window.scrollY - 80,
	behavior: "smooth"});
	});
	}

	function render(){
	const d = t(), W = DATA.season.weights, max = Math.max(1, ...DATA.entries.map(e=>e.total\|\|0));
	$("#wts").innerHTML = Object.entries(W)
	.map(([k,v])=>`<span>${(d.ov_axes[k]\|\|k)} <b>${v}</b></span>`).join("");
	$("#counts").textContent = d.counts(DATA.counts.scored, DATA.counts.anchors);

	$("#head").innerHTML = COLS.map(k=>{
	const on = sortKey===k;
	const ar = on ? (sortDir<0 ? "▼" : "▲") : "▾";
	return `<th data-k="${k}" class="${on?"sorted":""}">${d.cols[k]}<span class="ar">${ar}</span></th>`;
	}).join("");
	document.querySelectorAll("#head th").forEach(th=>th.onclick=()=>{
	const k = th.dataset.k;
	if(sortKey===k) sortDir = -sortDir;
	else { sortKey = k; sortDir = (k==="rank"\|\|k==="cand"\|\|k==="who") ? 1 : -1; }
	page = 0; // a new sort means a different first page
	render();
	});

	const all = DATA.entries.slice().sort((a,b)=>{
	const x = sortVal(a,sortKey), y = sortVal(b,sortKey);
	if(x<y) return -sortDir; if(x>y) return sortDir; return 0;
	});

	// Clamp before slicing: switching to a shorter season while deep in the pages of a
	// longer one would otherwise land on an empty table.
	const pages = Math.max(1, Math.ceil(all.length / PAGE_SIZE));
	if(page >= pages) page = pages - 1;
	if(page < 0) page = 0;
	const from = page * PAGE_SIZE;
	const rows = all.slice(from, from + PAGE_SIZE);
	renderPager(all.length, pages);

	$("#rows").innerHTML = rows.length ? rows.map(e=>{
	const a = e.axes\|\|{};
	const cls = [e.is_anchor?"anchor":"", e.tier===2?"tier2":""].join(" ").trim();
	const _who = e.hf_user \|\| e.display_name \|\| "";
	const user = e.is_anchor ? '<span class="who">\u2014</span>'
	: (e.hf_user ? hfProfile(e.hf_user)
	: `<span title="${esc(_who)}">${esc(e.display_name\|\|"\u2013")}</span>`);
	const _m = e.is_anchor ? (anchorNote(e) \|\| d.ref) : (e.model_name \|\| "\u2013");
	const who = `<span class="who" title="${esc(_m)}">${esc(_m)}</span>`;
	// the structure is the name now; a withheld one shows its ends, middle blanked.
	// Only a published structure gets a copy button - there is nothing to copy otherwise.
	const isPub = e.visibility === "public" && !!e.smiles;
	const shown = isPub ? e.smiles : e.smiles_masked;
	const clip = shown ? (shown.length > 26 ? shown.slice(0, 26) + "\u2026" : shown) : "";
	const id = e.is_anchor ? `<b>${e.candidate_id}</b>`
	: (shown
	? `<span class="smiwrap"><span class="smi2" title="${shown}">${clip}</span>`
	+ (isPub ? `<button class="d3" data-smi="${e.smiles}" title="${d.view_3d}">3D</button>`
	+ `<button class="cp" data-smi="${e.smiles}" title="${d.copy_smiles}">\u29c9</button>` : "")
	+ `</span>`
	: `<span class="cid">${e.candidate_id}</span>`);
	const tag = e.is_anchor ? `<span class="tag a">${d.anchor}</span>`
	: (e.tier===2 ? `<span class="tag r">${d.relegated}</span>` : "");
	// 반응성 경보. 판결이 아니라 사실이므로 등수를 깎지 않고 옆에 적기만 한다.
	const alr = (e.alerts && e.alerts.length)
	? `<span class="tag w" title="${e.alerts.join(", ")}">${d.reactive}</span>` : "";
	// 총점 옆의 ±. 잰 값에는 폭이 있고, 그 폭을 감추면 순위가 실제보다 확실해 보인다.
	const sdTxt = (e.total_sd!=null && e.total_sd>0) ? `<span class="sd">±${f1(e.total_sd)}</span>` : "";
	const rk = e.rank==null ? "—"
	: `#${e.rank}<span class="rkscore">${f3(e.total)}${LANG==="ko"?"점":" pts"}${sdTxt}</span>`;
	return `<tr class="${cls}">
	<td class="rk ${e.rank===1?"top":""}">${rk}</td>
	<td>${id}${tag}${alr}</td><td>${user}</td><td>${who}</td><td>${submittedDate(e)}</td>
	${AX.map(k=>`<td>${f1(a[k])}</td>`).join("")}
	<td><div class="barwrap"><span class="bar"><i style="width:${Math.max(2,(e.total\|\|0)/max*100)}%"></i></span>
	<span class="tot">${f3(e.total)}</span></div></td></tr>`;
	}).join("") : `<tr><td colspan="12" class="who">${d.empty}</td></tr>`;

	wireCopy($("#rows"));
	wire3D($("#rows"));

	// rows carry their entry so the overlay never has to look anything up again
	[...document.querySelectorAll("#rows tr")].forEach((tr, i) => {
	const e = rows[i];
	if(!e) return;
	tr.onmouseenter = () => { clearTimeout(OV._t); showOverlay(e, tr.getBoundingClientRect()); };
	// a short grace period, so moving the pointer into the panel does not dismiss it
	tr.onmouseleave = () => { OV._t = setTimeout(hideOverlay, 220); };
	// touch has no hover, so a tap toggles it
	tr.onclick = () => (OV.style.display === "block" && OV.dataset.id === e.candidate_id)
	? hideOverlay()
	: (OV.dataset.id = e.candidate_id, showOverlay(e, tr.getBoundingClientRect()));
	});
	}

	let ME = {signed_in:false, oauth_configured:false};
	let MODELS = {models:[], totals:{models:0, submissions:0}};

	function seasonClosed(){
	const si = seasonInfo();
	return si ? !si.open : false;
	}

	function renderAuth(){
	const d = t(), bar = $("#authbar"), gate = $("#gate"), go = $("#go");
	if(seasonClosed()){
	// the server refuses these posts anyway; saying so here saves someone writing out an
	// entry and being turned away after
	bar.innerHTML = "";
	gate.innerHTML = `<div class="lock">\u{1F6A7} ${d.season_notopen}</div>`;
	go.disabled = true;
	return;
	}
	if(ME.signed_in){
	const u = ME.user \|\| {};
	bar.innerHTML = '<span class="u">' + (u.picture ? `<img src="${u.picture}" alt="">` : "")
	+ (u.name\|\|"") + `<a href="logout">${d.signout}</a></span>`;
	gate.style.display = "none"; go.disabled = false;
	}else{
	bar.innerHTML = `<a class="hfbtn" href="login">\u{1F917} ${d.signin}</a>`;
	// when OAuth is not configured (a local run) the form stays usable so the rest of
	// the flow can still be exercised
	const need = ME.oauth_configured;
	gate.style.display = need ? "block" : "none";
	gate.innerHTML = need ? d.gate + `<a class="hfbtn" href="login">\u{1F917} ${d.signin}</a>` : "";
	go.disabled = need;
	}
	}

	function renderModels(m){
	const d = t();
	$("#mcounts").textContent = d.mcounts(m.totals.models, m.totals.submissions);
	$("#chart_sub").innerHTML = d.chart_sub;
	$("#legend").innerHTML =
	`<span><i style="background:linear-gradient(90deg,#0f7b6c,#2aa694)"></i>${d.lg_best}</span>`
	+ `<span><i style="background:#123;width:3px;height:12px;border-radius:1px"></i>${d.lg_mean}</span>`
	+ `<span><i style="background:#9db4d6"></i>${d.lg_use}</span>`;
	if(!m.models.length){ $("#models").innerHTML = `<p class="who">${d.chart_empty}</p>`; return; }
	const maxScore = Math.max(1, ...m.models.map(x=>x.best\|\|0));
	const maxUse = Math.max(1, ...m.models.map(x=>x.submissions\|\|0));
	$("#models").innerHTML = m.models.map(x=>
	'<div class="mrow">'
	+ `<div class="mname"${(x.spellings&&x.spellings.length>1)?` title="${esc(x.spellings.join(" · "))}"`:""}>`
	+ `${esc(x.model)}${(x.spellings&&x.spellings.length>1)?` <b class="mmerge">+${x.spellings.length-1}</b>`:""}`
	+ `<span>${x.entrants} ${d.entrants}</span></div>`
	+ '<div class="mtrack">'
	+ `<div class="best" style="width:${Math.max(4,(x.best\|\|0)/maxScore*100)}%"></div>`
	+ (x.mean!=null ? `<div class="mean" style="left:${Math.max(1,x.mean/maxScore*100)}%"></div>` : "")
	+ `<div class="lab">${f3(x.best)}</div>`
	+ '</div>'
	+ '<div class="muse">'
	+ `<span class="ub" style="width:${Math.max(3,(x.submissions/maxUse)*74)}px"></span>`
	+ `<span class="un">${x.submissions}</span>`
	+ '</div></div>').join("");
	}

	// The guide is per season, and it was not until 2026-08-19. PROMPTS was written for
	// season 1 and every later season served it unchanged, so an entrant on the Chagas
	// board pressed Copy and was handed a prompt beginning "You are designing
	// small-molecule inhibitors of PfDHODH ... for an open antimalarial challenge". The
	// point values in the subtitles were season 1's too. Nothing about the rubric moved
	// here; the instructions were simply describing a different disease.
	//
	// Prompt E is shared on purpose - reading your own axis scores back into the next
	// design is the same exercise whichever disease you are working on.
	const PROMPTS_BY_SEASON = {
	1: [{id:"A", ko:["기본형","처음 시작한다면 이것부터"], en:["Starter","Begin here"],
	body:`You are designing small-molecule inhibitors of PfDHODH, the dihydroorotate
	dehydrogenase of Plasmodium falciparum, for an open antimalarial challenge.

	Requirements:
	- The compound must inhibit the PARASITE enzyme and NOT the human DHODH. The human
	enzyme is homologous; inhibiting it causes immunosuppression rather than a cure.
	- It has to kill the parasite in a whole cell, which means crossing a red blood cell
	membrane and then the parasite membrane before the target is reachable.
	- Molecular weight under 500. No PAINS motifs. No covalent warheads. Synthesisable.

	Propose 8 candidates as a JSON array:
	[{"smiles":"...","name":"...","rationale":"why this should be selective for the
	parasite enzyme and reach it in a cell"}]

	<em>VARY THIS: state a chemotype you are interested in, or a constraint of your own, so
	your set does not collide with other entrants. Identical submissions are rejected.</em>`},

	{id:"B", ko:["선택성 집중","사람 효소를 피하는 설계 (20점)"], en:["Selectivity","Avoid the human enzyme (20 pts)"],
	body:`Design PfDHODH inhibitors with a deliberate selectivity argument against human
	DHODH.

	Context you should reason from:
	- Teriflunomide and brequinar inhibit the HUMAN enzyme. They are the failure mode here,
	not the template.
	- The inhibitor-binding site of the parasite enzyme differs from the human one in
	residue composition and shape. Design into that difference on purpose and say which
	difference you are exploiting.
	- A molecule that binds neither enzyme is trivially "selective" and worthless. Potency
	against the parasite enzyme is a precondition, not a trade-off.

	For each candidate, state explicitly: which feature you expect the human enzyme to
	tolerate poorly, and why.

	Propose 8 candidates as JSON: [{"smiles","name","rationale"}]

	<em>VARY THIS: pick one specific selectivity hypothesis and build the whole set around
	it, rather than eight unrelated guesses.</em>`},

	{id:"C", ko:["신규 골격","가장 큰 점수 여지 (신규성 10점)"], en:["Novel scaffold","Where the headroom is (10 pts)"],
	body:`Design PfDHODH inhibitors on scaffolds that do NOT appear in the antimalarial
	literature.

	Why this matters for scoring: novelty is measured as structural distance from known
	antimalarial chemical space, and it is MULTIPLIED by how potent the molecule is.
	- A novel but inactive molecule earns nothing.
	- A potent analogue of a known drug also earns nothing - the reference compound itself
	scores zero on novelty, and an analogue inherits that.
	- The points are only available to something both new and real.

	Explicitly avoid: DSM265 and other triazolopyrimidines, Genz-667348, and published
	PfDHODH inhibitor series. Do not decorate a known core - change the core.

	Propose 8 candidates on eight DIFFERENT cores, as JSON:
	[{"smiles","name","rationale":"why this core is unexplored here and why it should still
	bind"}]

	<em>VARY THIS: name two or three ring systems you want explored, so your set is yours.</em>`},

	{id:"D", ko:["전세포 투과","이중막을 통과해야 한다 (30점)"], en:["Whole-cell","Two membranes to cross (30 pts)"],
	body:`Design PfDHODH inhibitors optimised for actually killing the parasite in an
	infected red blood cell, not just for binding the isolated enzyme.

	The compound must cross the erythrocyte membrane and then the parasite membrane before
	the target matters. Enzyme affinity that never reaches the enzyme scores nothing.

	Reason explicitly about, for each candidate:
	- lipophilicity and polar surface area in a range compatible with passive permeability
	- the number of hydrogen-bond donors, and whether it is low enough
	- ionisation at the pH of the parasite's compartments
	- metabolic stability - the compound must survive long enough to matter

	Propose 8 candidates as JSON: [{"smiles","name","rationale":"the permeability argument,
	not only the binding argument"}]

	<em>VARY THIS: fix your own target property window before generating, and hold the set
	to it.</em>`},

	{id:"E", ko:["점수 되먹이기","받은 결과로 다음 판을 설계"], en:["Iterate","Feed your score back in"],
	body:`Here is how my previous candidate was scored on this challenge. Improve on it.

	PASTE YOUR RESULT HERE - hover your row on the leaderboard and copy the numbers:
	candidate id, total, and the six axis scores with their stated reasons
	(predicted potency against each enzyme, the selectivity ratio, the nearest known
	compound, the synthesis difficulty)

	Diagnose which axis is costing the most, then propose 8 revised candidates that attack
	that axis specifically, while not giving back what already scored well.

	Be honest about trade-offs: if improving selectivity is likely to cost whole-cell
	activity, say so and show both options.

	JSON: [{"smiles","name","rationale":"which axis this targets and what it trades"}]

	<em>VARY THIS: your own scores make this prompt unique - no two entrants have the
	same starting point.</em>`},
	],
	2: [
	{id:"A", ko:["기본형","처음 시작한다면 이것부터"], en:["Starter","Begin here"],
	body:`You are designing small-molecule inhibitors of InhA, the enoyl-ACP reductase of
	Mycobacterium tuberculosis, for an open tuberculosis challenge.

	Requirements:
	- The compound must inhibit the BACTERIAL enzyme and NOT the enoyl-reductase domain of
	human fatty acid synthase. The human enzyme runs the same chemistry; inhibiting it
	stops our own fatty-acid synthesis.
	- InhA works as a complex with NAD. Inhibitors that stack against the bound cofactor are
	a well-trodden route.
	- It has to work in a whole cell. M. tuberculosis has an unusually thick, waxy cell wall,
	so permeability is a harder constraint here than in most bacteria.
	- Do NOT submit a prodrug. Isoniazid is inactive until the bacterium's own KatG converts
	it; we score the molecule you submit, not what it might become.
	- Molecular weight under 550. No PAINS motifs. Synthesisable.

	Propose 8 candidates as a JSON array:
	[{"smiles":"...","name":"...","rationale":"why this should be selective for the
	bacterial enzyme and reach it through the mycobacterial cell wall"}]

	<em>VARY THIS: state a chemotype you are interested in, or a constraint of your own, so
	your set does not collide with other entrants. Identical submissions are rejected.</em>`},
	{id:"B", ko:["선택성 집중","사람 효소를 피하는 설계 (25점)"], en:["Selectivity","Avoid the human enzyme (25 pts)"],
	body:`Design InhA inhibitors with a deliberate selectivity argument against the enoyl-reductase
	domain of human fatty acid synthase.

	Context you should reason from:
	- Both enzymes reduce an enoyl thioester using NAD(P)H. The chemistry is shared; the
	surroundings are not.
	- InhA accepts very long-chain (C16-C24) substrates and has a correspondingly large,
	hydrophobic substrate-binding loop. Human FASN handles shorter chains. Design into that
	difference on purpose and say which difference you are exploiting.
	- A molecule that binds neither enzyme is trivially "selective" and worthless. Potency
	against InhA is scored separately and selectivity is scaled by it.

	Return 8 candidates as JSON with a "selectivity_rationale" field naming the specific
	structural feature you are exploiting.`},
	{id:"C", ko:["신규 골격","가장 큰 점수 여지 (신규성 10점)"], en:["Novel scaffold","Where the headroom is (10 pts)"],
	body:`Propose InhA inhibitors on scaffolds that are NOT represented among known
	anti-tubercular chemistry.

	Explicitly avoid: isoniazid-like hydrazides, thioamides (ethionamide, prothionamide),
	diarylquinolines, nitroimidazoles, oxazolidinones (linezolid-like) and fluoroquinolones.

	Novelty is scored as distance from known anti-tubercular chemical space, and it is
	MULTIPLIED by potency - a novel molecule that does nothing scores zero on that axis. So
	the target is a genuinely new scaffold that still makes a credible binding argument
	against the InhA-NAD complex.

	Return 8 candidates as JSON, each with the scaffold class named and one sentence on why
	it can still engage the site.`},
	{id:"D", ko:["전세포 활성","밀랍 세포벽을 통과해야 한다 (20점)"], en:["Whole-cell","Through a waxy wall (20 pts)"],
	body:`Design InhA inhibitors with mycobacterial cell entry as the primary constraint.

	What makes this hard:
	- The mycobacterial envelope is a thick mycolic-acid layer, far less permeable than a
	typical Gram-negative outer membrane. Many potent enzyme inhibitors fail entirely at
	the whole-cell step.
	- Efflux is active in M. tuberculosis and removes many otherwise good compounds.
	- Compounds are scored on whole-cell growth inhibition as well as on binding, so an
	inhibitor that cannot get in is scored as what it is.

	Return 8 candidates as JSON with a "permeability_rationale" field. State the logP,
	polar surface area and any efflux-avoidance reasoning you used.`},
	{id:"E", ko:["점수 되먹이기","받은 결과로 다음 판을 설계"], en:["Iterate","Feed your score back in"],
	body:`Here is how my previous candidate was scored on this challenge. Improve on it.

	PASTE YOUR RESULT HERE - hover your row on the leaderboard and copy the numbers:
	candidate id, total, and the six axis scores with their stated reasons
	(predicted potency against each enzyme, the selectivity ratio, the nearest known
	compound, the synthesis difficulty)

	Diagnose which axis is costing the most, then propose 8 revised candidates that attack
	that axis specifically, while not giving back what already scored well.

	Be honest about trade-offs: if improving selectivity is likely to cost whole-cell
	activity, say so and show both options.

	JSON: [{"smiles","name","rationale":"which axis this targets and what it trades"}]

	<em>VARY THIS: your own scores make this prompt unique - no two entrants have the
	same starting point.</em>`}
	],
	3: [
	{id:"A", ko:["기본형","처음 시작한다면 이것부터"], en:["Starter","Begin here"],
	body:`You are designing small-molecule inhibitors of CYP51, the sterol 14a-demethylase of
	Trypanosoma cruzi, for an open Chagas disease challenge.

	Requirements:
	- The compound must inhibit the PARASITE enzyme and NOT human CYP51A1. We run the same
	enzyme on the same chemistry, and inhibiting it is where the azole antifungals get
	their side effects.
	- CYP51 is a haem enzyme. Inhibitors classically coordinate the haem iron through a ring
	nitrogen. A molecule that does only that will not be selective, because our enzyme has
	the same iron - the selectivity has to come from somewhere else.
	- It has to work in a whole cell. T. cruzi persists inside host cells as an amastigote,
	so the compound must cross the host cell membrane and then the parasite's.
	- Do NOT submit a prodrug. Benznidazole and nifurtimox are nitro compounds activated by
	a parasite nitroreductase; we score the molecule you submit, not what it becomes.
	- Molecular weight under 750. Synthesisable.

	Propose 8 candidates as a JSON array:
	[{"smiles":"...","name":"...","rationale":"why this should be selective for the parasite
	enzyme and reach it inside a host cell"}]

	<em>VARY THIS: state a chemotype you are interested in, or a constraint of your own, so
	your set does not collide with other entrants. Identical submissions are rejected.</em>`},
	{id:"B", ko:["선택성 집중","사람 효소를 피하는 설계 (30점)"], en:["Selectivity","Avoid the human enzyme (30 pts)"],
	body:`Design T. cruzi CYP51 inhibitors with a deliberate selectivity argument against human
	CYP51A1.

	Context you should reason from:
	- Both enzymes strip the 14a-methyl group off a sterol precursor at a haem iron. The
	catalysis is shared; the channel that admits the substrate is not.
	- The parasite makes ergosterol-like sterols and we make cholesterol by way of
	lanosterol, and the hydrophobic substrate channels differ accordingly. Design into that
	difference on purpose and name the difference you are exploiting.
	- This is the axis nobody has cleared. The approved azoles inhibit the human enzyme about
	as hard as the parasite's, which is why they are tolerated the way they are. Matching
	them is not the target.
	- A molecule that binds neither enzyme is trivially "selective" and worthless. Potency
	against the parasite enzyme is scored separately and selectivity is scaled by it.

	Return 8 candidates as JSON with a "selectivity_rationale" field naming the specific
	structural feature you are exploiting.`},
	{id:"C", ko:["신규 골격","가장 큰 점수 여지 (신규성 10점)"], en:["Novel scaffold","Where the headroom is (10 pts)"],
	body:`Propose T. cruzi CYP51 inhibitors on scaffolds that are NOT represented among known
	anti-trypanosomal chemistry.

	Explicitly avoid: imidazole and triazole azoles of the ketoconazole or posaconazole type,
	nitroimidazoles and nitrofurans, and close analogues of either.

	Novelty is scored as distance from known anti-T. cruzi chemical space, and it is
	MULTIPLIED by potency - a novel molecule that does nothing scores zero on that axis. So
	the target is a genuinely new scaffold that still makes a credible argument for engaging
	a haem-containing active site.

	Return 8 candidates as JSON, each with the scaffold class named and one sentence on why
	it can still engage the site.`},
	{id:"D", ko:["전세포 활성","숙주 세포 안까지 들어가야 한다 (10점)"], en:["Whole-cell","Reach inside a host cell (10 pts)"],
	body:`Design T. cruzi CYP51 inhibitors with entry into an infected host cell as the primary
	constraint.

	What makes this hard:
	- T. cruzi persists as an intracellular amastigote, most importantly in cardiac muscle.
	A compound has to cross the host cell membrane and then reach the parasite inside it.
	- Chronic Chagas disease is treated for weeks to months. A compound that only works at a
	concentration nobody can sustain is not a candidate.
	- Compounds are scored on whole-cell growth inhibition as well as on binding, so an
	inhibitor that cannot get in is scored as what it is.

	Return 8 candidates as JSON with a "permeability_rationale" field. State the logP, polar
	surface area and any reasoning about intracellular accumulation you used.`},
	{id:"E", ko:["점수 되먹이기","받은 결과로 다음 판을 설계"], en:["Iterate","Feed your score back in"],
	body:`Here is how my previous candidate was scored on this challenge. Improve on it.

	PASTE YOUR RESULT HERE - hover your row on the leaderboard and copy the numbers:
	candidate id, total, and the six axis scores with their stated reasons
	(predicted potency against each enzyme, the selectivity ratio, the nearest known
	compound, the synthesis difficulty)

	Diagnose which axis is costing the most, then propose 8 revised candidates that attack
	that axis specifically, while not giving back what already scored well.

	Be honest about trade-offs: if improving selectivity is likely to cost whole-cell
	activity, say so and show both options.

	JSON: [{"smiles","name","rationale":"which axis this targets and what it trades"}]

	<em>VARY THIS: your own scores make this prompt unique - no two entrants have the
	same starting point.</em>`}
	]
	};
	function promptsFor(){ return PROMPTS_BY_SEASON[SEASON] \|\| PROMPTS_BY_SEASON[1]; }

	// Listed under the slugs Polaris itself uses, so each one can be looked up rather than
	// taken on trust. All sixteen were checked against the live Polaris benchmark index.
	// The sixteenth - adme-fang-perm - is the Biogen ADME permeability track, described
	// there as "LOG_MDR1-MDCK_ER"; it postdates the engine's own capability list, which is
	// why that list still reads fifteen.
	const BOARDS = ["hia-hou","bioavailability-ma","vdss-lombardo","solubility-aqsoldb",
	"cyp2d6-substrate-carbonmangels","ames","dili","moleculeace-chembl234-ki",
	"moleculeace-chembl236-ki","pkis2-egfr-wt-reg-v2","pkis2-egfr-wt-r-1",
	"pkis1-egfr-wt-mut-r-1","pkis1-egfr-wt-mut-c-1","pkis2-lok-slk-c-1",
	"pkis1-kit-wt-mut-r-1","adme-fang-perm"];

	function reasonText(r){
	// r is {code, arg, limit, text}; older records may still be a bare string
	if(typeof r === "string") return r;
	const f = t().reasons[r.code];
	return f ? f(r) : (r.text \|\| r.code \|\| "");
	}

	const OV = document.getElementById("ov");
	const WMAX = {activity:30, binding:20, selectivity:20, admet:15, novelty:10, synthesis:5};

	function ic50(logUM){
	// boltz reports log10(IC50 in uM); show it in whichever unit reads naturally
	if(logUM==null) return "–";
	const uM = Math.pow(10, logUM);
	return uM < 1 ? (uM*1000).toFixed(1)+" nM" : uM.toFixed(2)+" \u00B5M";
	}

	// falls back to the Korean note rather than to nothing: a reference row with no
	// explanation beside it is worse than one explained in the other language
	function anchorNote(e){
	return (LANG === "en" ? (e.note_en \|\| e.note) : e.note) \|\| "";
	}

	function overlayHTML(e){
	const d = t(), det = e.detail \|\| {}, ax = e.axes \|\| {};
	if(!Object.keys(ax).length) return `<h4>${e.candidate_id}</h4><div class="oid">${d.ov_none}</div>`;
	const rows = Object.keys(WMAX).map(k=>{
	const pts = ax[k], max = WMAX[k];
	const why = (det[k] && d.ov_why[k]) ? d.ov_why[k](det[k]) : "";
	return `<div class="orow"><span class="oax">${d.ov_axes[k]}</span>
	<span class="obar"><i style="width:${Math.max(2,(pts\|\|0)/max*100)}%"></i></span>
	<span class="opt">${(pts??0).toFixed(1)}</span>
	${why?`<span class="why">${why}</span>`:""}</div>`;
	}).join("");
	const r = e.run \|\| {}, sel = det.selectivity \|\| {};
	const pred = (r.aff_pf!=null \|\| r.aff_hs!=null) ? `<div class="osum">
	${d.ov_pred} · ${d.ov_pf} <b>${ic50(r.aff_pf)}</b> · ${d.ov_hs} <b>${ic50(r.aff_hs)}</b>
	${sel.fold?` · ${d.ov_sel} <b>${sel.fold}x</b>`:""}</div>` : "";
	const flag = (e.relegate_reason && e.relegate_reason.length)
	? `<div class="oflag">${e.relegate_reason.map(reasonText).join(" / ")}</div>` : "";
	const who = e.is_anchor ? anchorNote(e) : [e.hf_user, e.model_name].filter(Boolean).join(" · ");
	const full = (e.visibility === "public" && e.smiles) ? e.smiles : e.smiles_masked;
	const canCopy = e.visibility === "public" && e.smiles;
	const smi = e.is_anchor ? ""
	: `<div class="osmi">${full \|\| ""}`
	+ (canCopy ? `<button class="d3" data-smi="${e.smiles}" title="${d.view_3d}">3D</button>`
	+ `<button class="cp" data-smi="${e.smiles}" title="${d.copy_smiles}">\u29c9</button>` : "")
	+ (e.visibility === "public" ? "" : `<br>🔒 ${d.private_full}`) + `</div>`;
	return `<h4>${e.candidate_id}</h4><div class="oid">${who}${e.skeleton?" · "+e.skeleton:""}</div>`
	+ rows + pred + smi + flag + `<div class="ofoot">${d.ov_foot}</div>`;
	}

	// ---------------------------------------------------------------- 이정표
	// 🔴 숫자를 문구에 박지 않는다. 제출은 시간당 수십 건씩 들어와서, 박아두면
	// 반나절 만에 낡은 값이 공개면에 남는다. /api/totals 를 읽어 그때그때 그린다.
	async function paintMilestone(){
	const el = document.getElementById("milestone");
	if (!el) return;
	let d; try{ d = await j("/api/totals"); }catch(e){ return; }
	if (!d \|\| !d.submissions \|\| d.submissions < 10000) return; // 못 넘었으면 띄우지 않는다
	const n = d.submissions.toLocaleString();
	const p = (d.participants\|\|0).toLocaleString();
	const days = d.days;
	el.innerHTML = (LANG==="ko")
	? `🎉 <b>후보물질 <span class="n">${n}</span>건을 넘었습니다.</b> 개막 ${days}일, 참가자 ${p}명이 낸 것입니다.
	서로 알지도 못하는 분들이 같은 기준으로 겨뤄 만든 숫자입니다. 고맙습니다.`
	: `🎉 <b>Past <span class="n">${n}</span> candidate molecules.</b> ${days} days in, from ${p} participants —
	people who mostly do not know each other, measured on one rubric. Thank you.`;
	el.hidden = false;
	}

	// ---------------------------------------------------------------- countdown
	// end of the closing day, UTC. A deadline that lands at a different instant depending on
	// the entrant's timezone is not one, and the prize hangs off this date.
	let _deadline = null;

	function startCountdown(closes){
	const t = Date.parse(closes + "T23:59:59Z");
	if(isNaN(t)) return;
	_deadline = t;
	tickCountdown();
	clearInterval(startCountdown._i);
	startCountdown._i = setInterval(tickCountdown, 1000);
	}

	function tickCountdown(){
	if(!_deadline) return;
	const d = t(), box = $("#cd");
	// recomputed from the clock each tick rather than decremented, so a throttled or
	// suspended background tab comes back showing the right number instead of its own drift
	let ms = _deadline - Date.now();
	$("#cdlab").textContent = ms > 0 ? d.cd_label : d.cd_over_label;
	if(ms <= 0){
	box.classList.add("over");
	$("#cdval").textContent = d.cd_over;
	clearInterval(startCountdown._i);
	return;
	}
	box.classList.remove("over");
	const s = Math.floor(ms / 1000);
	const days = Math.floor(s / 86400);
	const p = n => String(n).padStart(2, "0");
	// 라벨이 이미 "마감까지" 라고 말한다. 앞에 빼기 기호를 붙여 두어서 남은 날이
	// 음수처럼 보였다 - 156일 남았는데 "-156일" 로 읽혔다.
	$("#cdval").innerHTML = `${days}<span class="d">${d.cd_day}</span> `
	+ `${p(Math.floor(s % 86400 / 3600))}:${p(Math.floor(s % 3600 / 60))}:${p(s % 60)}`;
	}

	// ---------------------------------------------------------------- 3D viewer
	// 3Dmol is loaded on first use. It is ~2 MB and most visits never open a structure, so
	// paying for it on every page load would be charging everyone for a minority feature.
	let _v3 = null, _3ready = null, _spin = true, _style = "stick";

	// out of the grid and onto the body: the modal was declared beside the hover overlay,
	// inside the layout, and the grid's min-width:0 collapsed it to nothing
	document.body.appendChild($("#m3"));

	function load3Dmol(){
	if(_3ready) return _3ready;
	_3ready = new Promise((res, rej) => {
	const s = document.createElement("script");
	s.src = "https://3Dmol.org/build/3Dmol-min.js";
	s.onload = res; s.onerror = () => rej(new Error("3Dmol"));
	document.head.appendChild(s);
	});
	return _3ready;
	}

	function paint3(){
	if(!_v3) return;
	_v3.setStyle({}, _style === "sphere"
	? {sphere:{scale:0.42, colorscheme:"Jmol"}}
	: {stick:{radius:0.17, colorscheme:"Jmol"}, sphere:{scale:0.22, colorscheme:"Jmol"}});
	_v3.render();
	}

	async function open3D(smi){
	const M = $("#m3"), msg = $("#m3m");
	M.classList.add("on");
	$("#m3s").textContent = smi;
	$("#m3f").textContent = ""; $("#m3w").textContent = "";
	msg.textContent = t().v3_loading;
	try{
	const [_, r] = await Promise.all([
	load3Dmol(),
	fetch("api/mol3d?smiles=" + encodeURIComponent(smi)).then(x => x.json())
	]);
	if(!r.mol) throw new Error("mol");
	$("#m3f").textContent = r.formula;
	$("#m3w").textContent = r.mw + " Da \u00b7 " + r.atoms + " " + t().v3_atoms;
	const host = $("#m3v");
	host.innerHTML = "";
	_v3 = $3Dmol.createViewer(host, {backgroundColor:"#0d1420"});
	_v3.addModel(r.mol, "mol");
	paint3();
	_v3.zoomTo();
	_v3.render();
	_v3.spin(_spin ? "y" : false, 0.6);
	msg.textContent = "";
	}catch(err){
	msg.textContent = t().v3_failed;
	}
	}

	function close3D(){
	$("#m3").classList.remove("on");
	// the WebGL context is not reclaimed by hiding the element; leaving one per open would
	// eventually exhaust the browser's context budget and blank the canvas
	try{ if(_v3){ _v3.spin(false); _v3.clear(); } }catch(_){}
	_v3 = null; $("#m3v").innerHTML = "";
	}

	$("#m3x").onclick = close3D;
	$("#m3").onclick = (e) => { if(e.target.id === "m3") close3D(); };
	document.addEventListener("keydown", e => { if(e.key === "Escape") close3D(); });
	$("#m3st").onclick = () => { _style = "stick"; $("#m3st").classList.add("on");
	$("#m3sp").classList.remove("on"); paint3(); };
	$("#m3sp").onclick = () => { _style = "sphere"; $("#m3sp").classList.add("on");
	$("#m3st").classList.remove("on"); paint3(); };
	$("#m3rt").onclick = () => { _spin = !_spin; $("#m3rt").classList.toggle("on", _spin);
	try{ if(_v3) _v3.spin(_spin ? "y" : false, 0.6); }catch(_){} };

	function wire3D(root){
	root.querySelectorAll(".d3").forEach(b => b.onclick = (ev) => {
	ev.stopPropagation();
	open3D(b.dataset.smi);
	});
	}

	function wireCopy(root){
	root.querySelectorAll(".cp").forEach(b => b.onclick = async (ev) => {
	// without this the click also reaches the row and toggles the overlay
	ev.stopPropagation();
	const v = b.dataset.smi;
	try{ await navigator.clipboard.writeText(v); }
	catch(_){ const ta=document.createElement("textarea"); ta.value=v;
	document.body.appendChild(ta); ta.select(); document.execCommand("copy"); ta.remove(); }
	b.classList.add("done"); b.textContent = "\u2713";
	setTimeout(()=>{ b.classList.remove("done"); b.textContent = "\u29c9"; }, 1200);
	});
	}

	function showOverlay(e, rect){
	OV.innerHTML = overlayHTML(e);
	OV.style.display = "block";
	const h = OV.offsetHeight, w = OV.offsetWidth;
	// flip above the row rather than open past the bottom of the window
	let top = rect.bottom + 8;
	if(top + h > window.innerHeight - 8) top = Math.max(8, rect.top - h - 8);
	// anchor to the right of the row: the structure and its copy button live on the left,
	// and opening over them buries the control the reader was reaching for
	let left = Math.max(8, Math.min(rect.right - w, window.innerWidth - w - 12));
	OV.style.top = top + "px";
	OV.style.left = left + "px";
	wireCopy(OV);
	wire3D(OV);
	}
	function hideOverlay(){ OV.style.display = "none"; }
	OV.onmouseenter = () => clearTimeout(OV._t);
	OV.onmouseleave = hideOverlay;

	async function load(){
	try{
	const [lb, me, md] = await Promise.all([
	fetch("api/leaderboard" + qs()).then(r=>r.json()),
	fetch("api/me").then(r=>r.json()).catch(()=>ME),
	fetch("api/models" + qs()).then(r=>r.json()).catch(()=>MODELS),
	]);
	DATA = lb; ME = me; MODELS = md;
	if(DATA.season && DATA.season.closes) startCountdown(DATA.season.closes);
	renderAuth(); render(); renderModels(MODELS);
	paintMilestone(); // 실패해도 본문은 그려져야 하므로 await 하지 않는다
	}
	catch(e){ $("#rows").innerHTML = `<tr><td colspan="11" class="who">${t().fail}${e}</td></tr>`; }
	}

	$("#go").onclick = async ()=>{
	const d = t(), btn = $("#go"), msg = $("#msg");
	const vis = (document.querySelector('input[name="vis"]:checked')\|\|{}).value \|\| "private";
	const body = {structure:$("#structure").value.trim(), display_name:$("#display_name").value.trim(),
	model_name:$("#model_name").value.trim(), rationale:$("#rationale").value.trim(),
	visibility: vis, season: SEASON};
	if(!body.structure \|\| !body.display_name){ msg.className="msg err"; msg.textContent=d.need; return; }
	btn.disabled = true; msg.className="msg"; msg.textContent="";
	try{
	const r = await fetch("api/submit" + qs(),{method:"POST",headers:{"Content-Type":"application/json"},body:JSON.stringify(body)});
	// 서버가 JSON 이 아닌 것을 돌려줄 수 있다 - 게이트웨이 오류 본문은 HTML 이다.
	// 그대로 파싱하면 참가자에게 "Unexpected token 'I'" 가 뜬다. 무슨 일이 났는지도,
	// 다시 내면 되는지도 알려주지 않는 문장이다.
	let j = null;
	try{ j = await r.json(); }catch(_){ j = null; }
	if(!j){ msg.className="msg err"; msg.textContent = r.status>=500 ? d.busy : (d.fail+r.status);
	btn.disabled=false; return; }
	if(j.accepted){ msg.className="msg ok"; msg.textContent=d.queued(j.candidate_id,j.queue_position,j.note);
	$("#structure").value=""; load(); }
	else { msg.className="msg err";
	msg.textContent=(j.reasons\|\|[]).map(reasonText).join(" / ") \|\| d.rejected; }
	}catch(e){ msg.className="msg err"; msg.textContent=d.fail+e; }
	btn.disabled = false;
	};

	document.querySelectorAll('input[name="vis"]').forEach(r => r.onchange = () => {
	$("#vis_priv").classList.toggle("on", r.value === "private" ? r.checked : !r.checked);
	$("#vis_pub").classList.toggle("on", r.value === "public" ? r.checked : !r.checked);
	});

	function renderPrompts(){
	const d = t(), host = $("#prompts");
	if(!host) return;
	host.innerHTML = promptsFor().map((p,i) => {
	const [title, sub] = (LANG==="ko" ? p.ko : p.en);
	return `<div class="pcard">
	<div class="phead"><span class="ptag">${p.id}</span>
	<b>${title}</b><span>${sub}</span>
	<button class="pcopy" data-i="${i}">${LANG==="ko"?"복사":"Copy"}</button></div>
	<div class="pbody">${p.body.trim()}</div></div>`;
	}).join("");
	host.querySelectorAll(".pcopy").forEach(b => b.onclick = async () => {
	// the emphasis markup is presentational; the clipboard gets clean text
	const raw = promptsFor()[+b.dataset.i].body.replace(/<\/?em>/g, "").trim();
	try{ await navigator.clipboard.writeText(raw); }
	catch(_){ const ta=document.createElement("textarea"); ta.value=raw;
	document.body.appendChild(ta); ta.select(); document.execCommand("copy"); ta.remove(); }
	const was = b.textContent;
	b.textContent = LANG==="ko" ? "복사됨 ✓" : "Copied ✓";
	setTimeout(()=>{ b.textContent = was; }, 1500);
	});
	}

	function seasonFacts(){
	const si = seasonInfo() \|\| {}, d = t();
	const W = si.weights \|\| {}, L = si.limits \|\| {};
	const names = LANG==="ko"
	? {activity:"약효", binding:"결합", selectivity:"선택성", admet:"ADMET",
	novelty:"신규성", synthesis:"합성"}
	: {activity:"Activity", binding:"Binding", selectivity:"Selectivity", admet:"ADMET",
	novelty:"Novelty", synthesis:"Synthesis"};
	const order = ["activity","binding","selectivity","admet","novelty","synthesis"];
	const line = order.filter(k => W[k] != null).map(k => names[k] + " " + W[k]).join(" · ");
	const total = order.reduce((a,k) => a + (W[k]\|\|0), 0);
	return {
	WEIGHTS: line + (LANG==="ko" ? `, 합계 ${total}점입니다.` : `, out of ${total}.`),
	MW: L.mw_max != null ? String(Math.round(L.mw_max)) : "550"
	};
	}

	function fillFacts(text){
	if(!text) return text;
	const f = seasonFacts();
	return String(text).replace(/\{(WEIGHTS\|MW)\}/g, (_, k) => f[k]);
	}

	function renderFails(){
	const d = t(), host = $("#fails");
	if(!host) return;
	host.innerHTML = (d.fails\|\|[]).map(([a,b]) => `<tr><td>${fillFacts(a)}</td><td>${fillFacts(b)}</td></tr>`).join("");
	}

	document.querySelectorAll("#tabs button").forEach(b => b.onclick = () => {
	document.querySelectorAll("#tabs button").forEach(x => x.classList.toggle("on", x===b));
	document.querySelectorAll(".panel").forEach(p =>
	p.classList.toggle("on", p.id === "p-" + b.dataset.panel));
	hideOverlay();
	window.scrollTo({top:0, behavior:"smooth"});
	});

	window.addEventListener("scroll", hideOverlay, {passive:true});
	window.addEventListener("resize", hideOverlay);

	fetch("api/seasons").then(r=>r.json()).then(j=>{ SEASONS = j.seasons; applyLang(); loadTally(); })
	.catch(()=>{});
	setInterval(loadTally, 600000);
	applyLang(); load(); setInterval(load, 20000);
	</script>
	</body>
	</html>